 
 
Protocol I6T -MC-AMAQ (b)  
 
A Safety, Tolerability, and Pharmacokinetic Study of 1- and 2-mL Injections of LY3074828 
Solution Using Investigational Pre- filled Syringes and Investigational Autoinjectors in Healthy 
Subjects  
 
[STUDY_ID_REMOVED]: [STUDY_ID_REMOVED] 
 Approval Date: 26-Jul-2018 
I6T - MC- AMAQ(b )C l in ica l  Pha rmaco logy  P ro toco l Page  1
LY3074828P ro toco lI6T - MC- AMAQ(b )
A  Sa fe ty,  To le rab i l i ty ,  and  Pha rmacok ine t ic  S tudy  o f  1 -and  
2 -mL  In jec t ions  o f  LY3074828  So lu t ion  Us ing
Inves t iga t iona l  P re- f i l led  Sy r inges  and  Inves t iga t iona l
Auto in jec to rs  in  Hea l thy  Sub jec ts
Con f iden t ia l  In fo rma t ion
The  in fo rma t ion  con ta ined  in  th is  p ro toco l  is  con f iden t ia l  and  is  in tended  fo r  the  use  o f  
c l in ica l  inves t iga to rs .   I t  is  the  p rope r ty  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies  and  
shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rsons  no t  invo lved  in  the  c l in ica l  inves t iga t ion  o f  
LY3074828,  un less  such  pe rsons  a re  bound  by  a  con f iden t ia l i ty  ag reemen t  w i th  E l i  L i l ly  
and  Company  o r  i ts  subs id ia r ies .
No te  to  Regu la to ry  Au tho r i t ies :  Th is  documen t  may  con ta in  p ro tec ted  pe rsona l  da ta  
and /o r  comme rc ia l ly  con f iden t ia l  in fo rma t ion  exemp t  f rom  pub l ic  d isc losu re .   E l i  L i l ly  and  
Company  reques ts  consu l ta t ion  rega rd ing  re lease / redac t ion  p r io r  to  any  pub l ic  re lease .   In  
the  Un i ted  S ta tes ,  th is  documen t  is  sub jec tto  F reedom  o f  In fo rma t ion  Ac t  (FO IA )  
Exemp t ion  4  and  may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  w r i t ten  
app rova l  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies .
App ro va l  Da te :  26 - Ju l -2018  GMTLY3074828
E l i  L i l l y  and  Compan y
Ind ianapo l i s ,  Ind iana  USA  46285
C l in i ca l  Pha rma co log y  P ro to co l  E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l l y:   
13De cembe r2017
Amendmen t  (b )E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l l y  on  da te  p ro v ided  be low .
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 2
LY3074828Table of Contents
A Safety , Tolerability , and Pharmacokinetic Study  of 1-and 
2-mL Injections of LY3074828 Solution Using Investigational 
Pre-filled Sy ringes andInvestigational Autoinjectors in 
Healthy  Subjects
Section Page
Protocol I6T -MC-AMAQ(b) A Safety, Tolerability, and Pharmacokinetic Study 
of 1-and 2 -mL Injections of LY3074828 Solution Using Investigational 
Pre-filled Syringes and Investigational Autoinjectors in Healthy Subjects ....................................... 1
Table of Contents .................................................................................................................................... 2
1. Protocol Synopsis ........................................................................................................................... 7
2. Sched ule of Activities ................................................................................................................... 10
3. Introduction .................................................................................................................................. 17
3.1. Study Rationale ....................................................................................................................... 17
3.2. Background ............................................................................................................................. 17
3.3. Benefit/Risk Assessment ......................................................................................................... 19
4. Objectives and Endpoints .............................................................................................................. 20
5. Study Design ................................................................................................................................ 21
5.1. Overall Design ........................................................................................................................ 21
5.2. Num ber of Participants ............................................................................................................ 22
5.3. End of Study Definition ........................................................................................................... 22
5.4. Scientific Rationale for Study Design ...................................................................................... 22
5.5. Justification for Dose ............................................................................................................... 23
6. Study Population .......................................................................................................................... 24
6.1. Inclusion Criteria ..................................................................................................................... 24
6.2. Exclusion Criteria .................................................................................................................... 26
6.3. Lifestyle and/or Dietary Requirements ..................................................................................... 29
6.3.1. Meals and Dietary Restrictions ....................................................................................... 29
6.3.2. Caffeine, Alcohol, and Tobacco ...................................................................................... 29
6.3.3. Activity .......................................................................................................................... 29
6.3.4. Blood and Plasma Donation ............................................................................................ 29
6.4. Screen Failures ........................................................................................................................ 29
7. Dosing Regimens .......................................................................................................................... 30
7.1. Dosing Regimens Administered............................................................................................... 30
7.1.1. Packaging and Labeling .................................................................................................. 32
7.2. Method of Treatment Assignment ............................................................................................ 32
7.2.1. Selection and Timing of Doses ....................................................................................... 32
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 3
LY30748287.3. Blinding .................................................................................................................................. 32
7.4. Dose Modification ................................................................................................................... 32
7.5. Preparation/Handling/Storage/Accountability .......................................................................... 32
7.6. Treatment Compliance ............................................................................................................ 33
7.7. Concomitant Therapy .............................................................................................................. 33
7.8. Treatment after the End of the Study ........................................................................................ 33
8. Discontinuation Criteria ................................................................................................................ 34
8.1. Discontinuation from Study Treatment .................................................................................... 34
8.1.1. Discontinuation of Inadvertently Enrolled Subjects ......................................................... 34
8.2. Discontinuation from the Study ............................................................................................... 34
8.3. Subjects Lost to Follow -up...................................................................................................... 34
9. Study Assessments and Procedures ............................................................................................... 35
9.1. Efficacy Assessments .............................................................................................................. 35
9.2. Adverse Events ....................................................................................................................... 35
9.2.1. Serious Adverse Events .................................................................................................. 36
9.2.1.1. Adverse Device Effects ............................................................................................. 37
9.2.1.2. Adverse Events of Special Interest ............................................................................ 37
9.2.1.3. Suspected Unexpected Serious Adverse Reactions .................................................... 37
9.2.1.4. Adverse Event Monitoring with a Systematic Questionnaire ..................................... 37
9.2.2. Complaint Handling ........................................................................................................ 38
9.3. Treatment of Overdose ............................................................................................................ 38
9.4. Safety ...................................................................................................................................... 38
9.4.1. Laboratory Tests ............................................................................................................. 38
9.4.2. Vital Signs ...................................................................................................................... 39
9.4.3. Electrocardiograms ......................................................................................................... 39
9.4.4. Other Tests ..................................................................................................................... 39
9.4.4.1. Tuberculosis Testing ................................................................................................. 39
9.4.4.2. Injection Instructions ................................................................................................ 40
9.4.4.3. Injection Speed Assessments and Video Recording ................................................... 40
9.4.4.4. Injection -site Assessments ........................................................................................ 40
9.4.4.5. Bleeding Assessment ................................................................................................ 40
9.4.4.6. Injection -site Pain ..................................................................................................... 40
9.4.4.6.1. Short Form McGill Pain Questionnaire ............................................................... 40
9.4.5. Safety Monitoring ........................................................................................................... 41
9.4.5.1. Hepatic Safety .......................................................................................................... 41
9.4.5.2. Monitoring of Hypersensitivity Reactions ................................................................. 41
9.5. Pharmacokinetics .................................................................................................................... 42
9.5.1. Bioanalysis ..................................................................................................................... 42
9.6. Pharmacodynamics .................................................................................................................. 42
9.6.1. Immunogenicity Assessments ......................................................................................... 42
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 4
LY30748289.7. Genetics .................................................................................................................................. 43
9.8. Biomarkers .............................................................................................................................. 44
9.9. Health Economics ................................................................................................................... 44
10. Statistical Considerations and Data Analysis ................................................................................. 45
10.1. Sample Size Determination ...................................................................................................... 45
10.2. Populations for Analyses ......................................................................................................... 45
10.2.1. Study Participant Disposition .......................................................................................... 45
10.2.2. Study Participant Characteristics ..................................................................................... 45
10.3. Statistical Analyses .................................................................................................................. 45
10.3.1. Safety Analyses .............................................................................................................. 46
10.3.1.1. Clinical Evaluation of Safety .................................................................................... 46
10.3.1.2. Statistical Evaluation of Safety ................................................................................. 46
10.3.1.2.1. Injection -site Pain ............................................................................................... 46
10.3.1.2.2. Duration of Injection .......................................................................................... 46
10.3.1.2.3. Injection -site Assessments .................................................................................. 47
10.3.1.2.4. Statistical Evaluation of Other Safety Parameters................................................ 47
10.3.2. Pharmacokinetic Analyses .............................................................................................. 47
10.3.2.1. Pharmacokinetic Parameter Estimation ..................................................................... 47
10.3.2.2. Pharmacokinetic Statistical Inference ........................................................................ 47
10.3.3. Pharmacodynamic Analyses ........................................................................................... 47
10.3.4. Pharmacokinetic/Pharmacodynamic Analyses ................................................................. 47
10.3.5. Evaluation of Immunogenicity ........................................................................................ 48
10.3.6. Data Review During the Study ........................................................................................ 48
10.3.7. Interim Analyses ............................................................................................................. 48
11. Refer ences .................................................................................................................................... 49
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 5
LY3074828List of Tables
Table Page
Table AMAQ.1. Objectives and Endpoints ................................................................................. 20
Table AMAQ.2. Dosing Regimens Administered –Part A ......................................................... 30
Table AMAQ.3. Dosing Regimens Administered –Part B .......................................................... 31
Table AMAQ.4. Amendment Summary for Protocol I6T -MC-AMAQ Amendment(b) ............... 60
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 6
LY3074828List of Appendices
Appendix Page
Appendix 1. Abbr eviations and Definitions .......................................................................... 50
Appendix 2. Clinical Laboratory Tests ................................................................................. 54
Appendix 3. Study Governance, Regulatory and Ethical Considerations ............................... 55
Appendix 4. Hepatic Monitoring Tests for Treatment -emer gent Abnormality ....................... 58
Appendix 5. Blood Sampling Summary ............................................................................... 59
Appendix 6. Protocol Amendment I6T -MC-AMAQ(b) Summary: A Safety, 
Tolerability, and Pharmacokinetic Study of 1-and 2 -mL Injections of 
LY3074828 Solution Using Investigational Pre -filled Syringes and 
Investigational Autoinjectors in Healthy Subjects ............................................. 60
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 7
LY30748281.Protocol Sy nopsis
Title of Study:
A Safety, Tolerability, and Pharmacokinetic Study of 1-and 2 -mL Injections of LY3074828 Solution 
Using Investigational Pre
-filled Syringe sand Investigational Autoinjector sin Healthy Subjects
Rationale: 
Study I6T -MC -AMAQ (AMAQ) will assess the pharmacokinetics (PK), safety and tolerability of, and pain
associated with, a 250- mg subcutaneous (SC) dose of LY3074828 solution formulation administered as 1 x 2-mL 
125-mg/mL injection using a n investigational manual pre -filled syringe (PFS ; Test 1 )and administered as 2 x 1-mL 
125-mg/mL injection susing a n investigational manual PFS ( Reference ).  The study  will also compare safety and
tolerability of, and pain associated with ,
a250-mg SC dose of LY3074828 solution formulation administered as 
1 x 2 -mL 125 -mg/mL injection using a ninvestigational 2-mL autoinjector (AI) with slow (Test 2) and fast (Test 3) 
injection speeds ,anda 125-mg dose administered as 1 x 1-mL 125 -mg/mL injection using a ninvestigational 1-mL 
AI with slow (Test 4) and fast (Test 5) injection speeds.  The study  will bridge 2 different PFSs administering the 
same total volume ,from 2 injections with the 1 -mL PFS used to administer LY3074828 solution in 
Study I6T-MC -
AMAE (AMAE) to 1 injection with a 2-mL investigational PFS.  Investigational 1 -and 2- mL AI 
administrations are to be evaluated primarily for pain and injection site reactions . 
Objectives/Endpoints:
Objectives Endpoints
Primary
Part A
To evaluate the PK of LY3074828 solution 
formulation after administration of 250 -mg 
doses using 2 x 1-mL and 1 x 2-mL PFS 
injections in healthy subjects.
To assess the safety and tolerability of, and 
pain associated with ,LY3074828 PFS 
administrations in healthy subjects.Part A
The primary PK endpoints will be the Cmax, 
AUC (0-tlast), and AUC(0-∞) of LY3074828.
Incidence of TEAEs.
SF-MPQ, including VAS pain score.
Primary
Part B
To compare the safety and tolerability of ,and 
pain associated with ,LY3074828 solution 
formulation after administration of 125 -and 
250-mg doses using 1 -mL AI and 2 - mL AI 
SC injections with different injection speeds 
(slow and fast) in healthy subjects.Part B
Incidence of TEAEs.
SF-MPQ, including VAS pain score.
Abbrev iations:  AI = autoinjector; AUC(0 -∞) = area under the concentration versus tim ecurve from time zero to 
infinity ; AUC(0 -tlast) = area under the concentration versus time curve from time zero to time t, where t is the 
last sample with a measurable concentr ation; C max= maximum observed drug concentration; PFS = pre -filled 
syringe; PK = pharmacokinetic; SC = subcutaneous; SF-MPQ = Short Form McGill Pain Questionnaire; 
TEAE = treatment -emergent adverse event; VAS = visual analog scale.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 8
LY3074828Summary of Study Design:
Study I6T-MC -AMAQ (AMAQ) is asingle-center, randomized, parallel - treatment, open -label, Phase 1 single -dose 
study of LY3074828 solution formulation in healthy subjects.  In Part A, PK, safety andtolerability of, and pain
associated with ,SC dose sadministered using 1-and 2- mL PFS injection swill be evaluated.  In Part B, safety and
tolerability of, and pain associated with , 1-and 2 -mL AI injections administered with 2 different injection speeds
will be evaluated .
For Part A, s ubjects will repor t to the clinical research unit (CRU) on Day -
1 and will remain at the CRU until the 
scheduled procedures have been completed on Day 2.  After randomization to either a 2 x 1-mL or a 1 x 2-mL 
125-mg/mL PFS dose regimen , study drug will be administered by investigative site staff by SC injection in the 
abdomen in the morning of Day 1 after an overnight fast.  Subjects will be followed for 12 weeks following dose 
administration.
For Part B, subjects will report to the CRU on Day -1 and will remain at the CRU until the scheduled procedures 
have been completed on Day 3.  Subjects will be randomiz ed to receive, on Days 1 and 2, either a 1
x 1-mL or a
1 x 2-mL 125- mg/mL AI dose regime n
.  The allocated AI dose regimen will be self-administered by slow and fast
SC injection (s
)on consecutive days (sequence randomized )in the abdomen after an overnight fast.  Subjects will be 
followed for 12 weeks following dose administration.
Safety and tolerability will be explored by clinical laboratory tests, vital sign measurements, 12 -lead 
electrocardiograms, recording of adverse events and product complaints , physical examinations/medical 
assessments , immunogenicity, and injection -site assessments.   Pain assessments will be made using t he Short Form 
McGill Pain Questionnaire (SF -MPQ), which includes a subject -assessed injection -site pain visual analog scale 
(VAS).
Dosing Regimen Arms and Duration:   
Subjects will receive a 125- or 250-mg SC dose of LY3074828 and will be randomized to 1 of 2 dosing regimen 
arms within 1study part :
Part A
Reference:  250mg LY3074828 solution formulation , 2 x 1 -mL 125 -mg
/mL PFS injections using an 
investigational PFS targeting 5- to 10-second injection time for each injection
Test 1:  250 mg LY3074828 solution formulation , 1
x 2-m L 125 -mg /mL PFS injection using an 
investigational PFS targeting 5- to 15-second injection time
Part B
Tests 2and 3
: 250mg LY3074828 solution formulation ,1 x 2-mL 125-mg/mL AIslow injection ( Test 2; 
targeting approx imately 13-second injection time) and fast injection ( Test 3; targeting approx imately
5-second injection time) using an investigational 2 -mL AI
Tests
4and 5:  125mg LY3074828 solution formulation , 1x 1-mL 125 -mg/mL AIslow injection ( Test 4; 
targeting approx imately 7-second injection time) and fast injection ( Test 5; targeting approx imately
4.5-second injection time) using an investigational 1 -mL AI
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 9
LY3074828Total duration of the study for each subject will be approximately 16 weeks ( screening period ≤28 days, residential 
period of 2 or 3 days[depending on study part] , and outpatient follow -up period of 12 weeks).
Number o
f Subjects:
A total of approximately 72 subjects (approximately 36 subjects per study Parts A and B )who fulfill the eligibility 
criteria will be randomized to 1 of 2 dosing regimen arms within their assigned study part, with 18 subjects 
randomized to each arm in order to ensure completion of 16 subjects in each.   A subject’s study particip ation is 
considered as complete if he/she receive sthe study  drug as per the protocol requirements and completes all activities 
up to and including at least Day 57 for Part A or up to and including at least Day 15for Part B .  A maximum of 
4subjects per arm per study part may be replaced if multiple subjects do not complete the study .
Statistical Analysis:
For Part A, t he area under the concentration versus time curve (AUC) from time zero to infinity (AUC [0-∞]), AUC
from time zero to time t, where t is the last sample with a measurable concentration (AUC[0 -tlast]),and maximum 
observed drug concentration ( Cmax)will be log -transformed and analyzed using a linear fixed -effects model.  The 
model will include dosing regimen arm as a fixed effect.  The dosing regimen differences between the T est 1 arm 
and the Reference arm will be back -transformed to present the ratios of geometric least squares (LS) means and the 
corresponding 90% confidence interval (CI).
The t ime toCmax(tmax) of LY3074828 between the 2 x 1-mL PFS (Reference) and the 1 x 2-mL PFS (Test 1) will 
be analyzed using a Wilcoxon rank sum test for Part A .  Estimates of the median difference, 90% CIs, and p -values 
from the Wilcoxon rank sum test will be calc ulated.
Additional PK analyses may be conducted for Part A if deemed appropriate. 
In Part A, a linear fixed -effects model will be used to analyze the 0-hour (post -injection) pain VAS score and 
SF
-MPQ total score.  The model will include treatment (Reference or Test 1) as a fixed effect .  The LS means and 
differences in LS means (between Test 1 and Reference) will be presented along with the corresponding 90% CI.
A similar model will be used to ana lyze the 0-hour (post -injection) pain VAS score and SF - MPQ total score in 
Part B.
The following comparisons will be performed in Part B:
Test 2 versus Test 3 (slow versus fast injection for 2 -mL AI)
Test 4 versus Test 5 (slow versus fast injection for 1 -mLAI) 
For Parts A and B, s afety  parameters will be listed and summarized using standard descriptive statistics.
Additional safety and tolerability analyses will be performed if warranted upon review of the data.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 10
LY30748282.Schedule of A ctivities
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 11
LY3074828Study Schedule Protoco l I6T-MC -AMAQ –Part A
Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
Informed consent X
Review / confirm 
inclusion/exclusion criteriaX X Any time prior to dosing.
Subject admission to CRU X
Subject discharge from CRU X
Outpatient visit X X X X X X X X X X X
Randomization XSubjects randomized to 1 x 2- mL or 2 x 1 -mL 
PFS arm .
LY3074828 injection X Doses administered by investigative site staff.
Stopwatch recording XStopwatch is the source for injection duration 
capture.
Medical history X
Weight, height, and BMI X
Vital signs:  blood pressure, 
pulse rate, temperature (hour)X X 0, 6 24 X X X X X X X XTimes with respect to start of dosing.  Single 
ECGs to be collected.  Zero -hour collection 
within 30 minutes before dosing.  Time 
allowance for 6-and 24 -hour time points:  
±30 and ±90 minutes, respectively.   For vital 
sign assessments, temperature need only be 
included at predose and when clinically 
indicated.12-lead ECG (hour) X 0 24 X
Physical examination / 
medical assessmentX X X X XFull physical examination/medical 
assessment at screening .  Symptom -directed 
physical examination/medical assessment at 
all other time points, and as deemed 
necessary by the investigator.
AE review X X X X X X X X X X X X X XAE only after signing ICF. Product 
complaints and device -related AEs collected 
as appropriate .
QuantiFERON ®-TB Gold 
test X
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 12
LY3074828Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
Serology X See Appendix 2 for test details.
Ethanol t est and urine drug 
screenX XMay be repeated at the discretion of the 
investigator.   Ethanol test may be either
breath o r urine testing.   See Appendix 2 for 
test details.
FSH / serum pregnancy test X X X X XSerum pregnancy tests for all female subjects
at screening and on Day -1,and only for 
women of childbearing potential on Days 29, 
57, and 85/ED .  Forallwomen who are 
considered to be postmenopausal, FSH should 
be drawn at screening to confirm 
postmenopausal status as defined in inclusio n 
criterion [1b]; women with confirmed 
postmenopausal status can be exempt ed from
further pregnancy tests during the study.   See 
Appendix 2 for test details.
Clinical chemistry, 
hematology, and urinalysisX X X X X X See Appendix 2 for test details.
Creatine phosphokinase X X X
Injection -site assessment for 
erythema, induration, 
categorical pain, pruritus, 
edema , and visible bleeding
(hour)0, 0.25 X X XTimes with respect to start of dosing.  
Zero-hour assessments within 5 minutes 
following injection.  Time allowance for 
0.25-hour assessment is ±5 minutes.  
Additional assessments performed if deemed 
necessary by the investigator.
Pain assessment (SF -MPQ, 
including pain VAS)XImmediately after the start of injection (t = 0) 
(within approximately 5 minutes) and at 15 
(±5), 30 (±5), 60 (±5), 120 (±10), and 240 
(±10) minutes post injection. For 1 -mL PFS, 
assessments to be completed on the first of 
the 2 injections only .
LY3074828 pharmacokinetic 
sampling (hour)0, 2, 6 24 72 168 240 336 504 672 1008 1344 1680 2016Times with respect to start of dosing.  
Zero-hour collection immediately (within 
15minutes) before dosing. Time allowance 
for 2 -, 6-, and 24 -hour time points:  ±15, ±30, 
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 13
LY3074828Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
and ±90 minutes ,respectively.
Immunogenicity sample Predose X X X X LY3074828 antibody sample.
Pharmacog enetics sample X
Abbreviat ions:   AE=adverse event; BMI = body mass index; CRU = clinical research unit; d =day; ECG =electrocardiogram; ED =early  discontinuation ; FSH 
= follicle -stimulating hormone; ICF=informed consent form ;PFS = pre -filled syringe; SF-MPQ = Short Form McGill Pain Questionnaire; 
TB=tuberculosis; VAS = visual analog scale.
Site should schedule activities as appropriate.  In cases where several study procedures are scheduled at the same time, foll ow this order of priority for 
procedures:   pharmacokinetic samples, ECG, vital signs, clinical laboratory tests , pain assessment , injection -site assessment, immunogenicity sample, stored 
sample, such that pharmacokinetic sample collection occurs as close to the nominal collection time as possible .  Procedures specified as predose may be 
performed within 2 hours from planned dosing.  
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 14
LY3074828Study Schedule Protoco l I6T -MC -AMAQ –Part B
Screening Days Comments
Procedure ≤28 days -1 1 2 315
±2d43
±2d86/ED
±3d
Informed consent X
Review / confirm 
inclusion/exclusion criteriaX X Any time prior to dosing.
Subject admission to CRU X
Subject discharge from CRU X
Outpatient visit X X X X
Randomization XSubjects randomized to 1-mL or 2 -mL AI arm, and then 
further randomized within the arm in respect to 
sequence of injection speed on Days 1 and 2 (slow/fast 
or fast/slow).
Injection training X
LY3074828 injection X X Doses self-administered.
Stopwatch and video recording X XStopwatch is the source for injection duration capture. 
Video recording for device functionality.
AI Use Assessment 
QuestionnaireX XClinical staff who observe the subject’s self -injection 
with the AI will fill out the AI Use Assessment 
Questionnaire
Medical history X
Weight, height, and BMI X
Vital signs:  blood pressure, 
pulse rate, temperature (hour)X X 0, 6 0, 6 24 X X XTimes with respect to start of dosing.  Single ECGs to 
be collected.  Zero-hour collection within 30 minutes 
before dosing.  Time allowance for 6 -and 24- hour time
points:  ±30 and ±90 minutes, respectively.  For vital 
sign assessments, temperature need on ly be included at 
predose and w hen clinically indicated.12-lead ECG (hour) X 0 0 24 X
Physical examination / medical 
assessmentX X X XFull physical examination/medical assessment at 
screening .  Symptom -directed physical 
examination/medical assessment at all other time points, 
and as deemed necessary by the investigator.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 15
LY3074828Screening Days Comments
Procedure ≤28 days -1 1 2 315
±2d43
±2d86/ED
±3d
AE review X X X X X X X XAE only after signing ICF. Product complaints and 
device -related AEs collected as appropriate .
QuantiFERON ®-TB Gold test X
Serology X See Appendix 2 for test details.
Ethanol test and urine drug 
screenX XMay be repeated at the discretion of the investigator.   
Ethanol test may be either breath or urine testing.   See 
Appendix 2 for test details.
FSH / serum pregnancy test X X X X XSerum pregnancy tests for all female subjects at 
screening and on Day -1,and only for women of 
childbearing potential on Days 15, 43, and 86/ED .  For 
allwomen who are considered to be postmenopausal, 
FSH should be drawn at screening to confirm 
postmenopausal status as defined in inclusio n criterion 
[1b]; women with confirmed postmenopausal status can 
be exempt ed from further pregnancy tests during the 
study.   See Appendix 2 for test details.
Clinical chemistry, 
hematology, and urinalysisX X X X X See Appendix 2 for test details.
Creatine phosphokinase X X X
Injection -site assessment (Day 
1 injection) for erythema, 
induratio n, categorical pain, 
pruritus, edema, and visible 
bleeding (hour)0, 0.25 24 XTimes with respect to start of dosing.  Zero -hour 
assessments within 5 minutes following injection.  Time 
allowance for 0.25 -hour assessment is ±5 minutes.  
Additional assessments performed if deemed necessary 
by the investigator.
Injection -site assessment (Day 
2 injection) for erythema, 
induratio n, categorical pain, 
pruritus, edema, and visible 
bleeding (hour)0, 0.25 24 XTimes with respect to start of dosing.  Zero -hour 
assessments within 5 minutes following injection.  Time
allowance for 0.25 -hour assessment is ±5 minutes.  
Additional assessments performed if deemed necessary 
by the investigator.  
Pain assessment (SF -MPQ, 
including p ain VAS)X XImmediately after the start of each injection (t = 0) 
(within approximately 5 minutes) and at 15 (±5), 30 
(±5), 60 (±5), 120 (±10), and 240 (±10) minutes post 
injection. 
LY3074828 pharmacokinetic X X X Samples collected to match immunogenicity collections.   
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 16
LY3074828Screening Days Comments
Procedure ≤28 days -1 1 2 315
±2d43
±2d86/ED
±3d
sampling Predose Samples will be stored and will o nlybe sent for 
bioanaly sis at a later date based on immunogenicity or 
safety results from Part B of the study.
Immunogenicity sample Predose X X X LY3074828 antibody sample.
Pharmacogenetics sample X
Abbreviations:   AE=adverse event; AI = autoinjector ;BMI = body mass index; CRU = clinical research unit; d =day; ECG =electrocardiogram; ED =early 
discontinuation ; FSH = follicle -stimulating hormone; ICF = informed consent form ;SF-MPQ = Short Form McGill Pain Questionnaire; TB=tuberculos is; 
VAS = visual analog scale.
Site should schedule activities as appropriate.  In cases where several study procedures are scheduled at the same time, foll ow this order of priority for 
procedures:  ECG, vital signs, clinical laboratory tests, pain assessm ent, injection -site assessment, immunogenicity and pharmacokinetic sample s, stored 
sample.  Procedures specified as predose may be performed within 2 hours from planned dosing.  
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 17
LY30748283.Introduction
3.1. Study Rationale
Study  I6T-MC-AMAQ (AMAQ) will assess the pharmacokinet ics (PK), safet y and tolerabilit y
of, and pain associ ated wi th,a 250 -mg subcutaneous (SC) dose of LY3074828 so lution
formulation administered as 1 x 2-mL 125 -mg/mL inject ion using a n invest igationalmanual 
pre-filled syringe (PFS; Test 1) and administered as 2 x 1-mL 125 -mg/mL inject ions using a n 
investigat ionalmanual PFS (Reference).  The study  will also com pare safety andtolerabilit yof, 
and pain associated wi th,a 250 -
mg SC dose of LY3074828 solut ion formulation administered as 
1 x 2- mL 125 -mg/mL inject ion using a n invest igatio nal2-mL autoinjector (AI) with slow 
(Test 2) and fast (Test 3) inject ion speeds and a 125-mg dose administered as a 1
x 1-mL 
125-mg/mL inject ion using a n invest igational1-mL AI with slow (Test 4) and fast (Test 5) 
inject ion speeds.  The study  will bri dge 2 different PFS sadministering the same total vo lume,
from 2 inject ions wi th the 1-mL PFS used to adminis ter LY3074828 sol ution in 
Study I6T-MC-AMAE (AMAE) to 1 inject ion with a 2-mL invest igational PFS.  Invest igational 
1-and 2 -mL AI administrations are to be evaluated primarily  for pain andinject ion-site 
reacti ons
.
3.2. Background
LY30 74828 i s a humanized immunoglobulin G4 -variant m onocl onal ant ibody  that i s directed 
against the p19 subunit of interleukin -23 (IL -23) and does not bind interleukin -12.  LY3074828 
is being developed for the treatment of autoimmune diseases in which the IL -23 pathway  is 
thought to have a significant pathogenic role.  Neutralizat ion of IL -23 wi th an ant i-mouse IL -23 
surrogate antibody  (directed against the p19 subunit) significant ly reduced the development of 
arthri tis and inhibited ileal inflammat ion in a mouse model of spondyloarthropathy  with bowel  
inflammat ion (Ruutu et al . 2012 ). Additionally ,neutralizat ion of IL -23 si gnificant ly reduced the 
disease score in the relapsing -remitt ing experimental autoimmune encephalo myelitis (mult iple 
sclerosi s-like) m odel in mice.  Anti -IL-23 ant ibody also demonstrated some efficacy in 
preclinical arthritis mod els, depending on the timing of intervent ion (Cornelissen et al. 2013 ).  
LY3074828 has been evaluated in 5 healt hy subjects (single 120- mg SC doses) and in 
33subjects with plaque psoriasis (single ascending intravenous [ IV]doses of 5, 20, 60, 120, 200, 
350, or 600 mg) in Study I6T-MC-AMAA (AMAA).  Furthermore, 43 healthy Japanese and 
Caucasian subjects were administered single IVdoses of 60, 200, 600, or 1200 mg LY3074828, 
or placebo, or single SC doses of 200 mg LY3074828, or placebo, in Study I6T-MC-AMAD
(AMAD).
No seri ous adverse events (SAEs) were reported in either study .  There were no drug -related 
treatm ent-emergent adverse events (TEAEs) of National Cancer Inst itute Commo n Termino logy 
Criteria for Adverse Events Grade 2 or higher reported in Stud y AMAA, and no infusio n 
reacti ons, injection -site reacti ons, or adverse events ( AEs)considered related to study  drug were 
reported in Study  AMAD.  There were no dose -dependent trends in AEs, or clinically important 
changes in vital signs, electrocardiograms (ECGs), or clinical laboratory  resul ts across both 
studi es that were consi dered to be related to the study  drug.  Pharm acokinetic resul ts obtained 
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 18
LY3074828from Study AMAA i ndicated that serum exposure of LY3074828 increases in a 
dose-proporti onal manner, and that the mean half -life associated with the terminal rate constant 
(t1/2) was 10.5 days, which did not appear to be dependent on dose.  Maximum concentrations 
were obser ved 3 days postdose following SC administration and ,based on the area under the 
concentration versus t ime curve (AUC), the SC bioavailabilit y was 40%.
Treatment -emergent ant i-drug antibodies (TE -ADAs) developed in 3 of 33 subjects after 
administration of single IV doses of LY3074828 in Study  AMAA; however, there was no 
correl ation between TE -ADA titers and the doses of LY3074828.  The earliest time point at 
which TE -ADAs were detected was Day 22, which was the first postdose time point at which 
immunogenic ity was assessed. The highest anti-drug antibody  (ADA )titer observed was 1:320.   
None of the healt hy subjects (n=5) who received 120 mg SC LY3074828 developed TE ADA. 
Treatment -emergent ADAs developed in 2 of 6subjects fo llowing single SC doses of 200 mg 
LY3074828 in Study  AMAD; however, ti ters were ≤1:160.
LY3074828 is currently being evaluated in three Phas e 2 studi es:
Study  I6T-MC-AMAC is being conducted in approximately  240 subjects wi th ulcerat ive 
colitis.  Three IV doses of 50, 200, or 600 mg LY30 74828 (or placebo) are administered 
every 4 weeks (Q4W) during the induct ion peri od.  Subj ects wi th a clinical  response are 
subsequent ly administered SC doses of 200 mg LY3074828 (or placebo) Q4W or 200 mg 
LY3074828 every 12 weeks during the 92- week mainte nance peri od.  Subj ects wi th no 
clinical response in the induct ion peri od may  be administered 3 further 1000 mg 
LY3074828 IV doses Q4W, fo llowed by 200 mg LY3074828 SC Q4W for 80 weeks. 
Study  I6T-MC-AMAF is being conducted in approximately 200 subjects wi th plaque 
psori asis.  Two SC doses of 30, 100, or 300 mg LY3074828 (or placebo) are 
administered every  8weeks (Q8W) during the induction period, followed by 30, 100, or 
300 m g Q8W or as requi red during the 88 -week maintenance period.
Study  I6T-MC-AMAG is to be conducted i n approximately  180 subjects wi th Crohn’s 
disease (CD).  Three IV doses of 200, 600, or 1000 mg LY3074828 (or placebo) will be 
administered Q4W.  LY3074828 -treated subjects with an improvement in CD score will 
either continue wit h this dos e regimen, or will be administered 300 mg LY3074828 SC 
Q4W, over a period of 40 weeks.  Subjects who receive placebo or who did not have a 
clinical improvement in CD score will receive 1000 mg LY3074828 IV Q4W.  Subjects 
with clinical  benefi t may cont inue with 300 m g LY3074828 SC Q4W for an additional 
52 weeks.
LY3074828 is currently being evaluated in 2 bioavailabilit y studies:
Study I6T-MC-AMAL is being conducted in approximately 72healt hy subjects.  The 
relative bioavailabilit y, abso lute bioavailabilit y,and tolerabilit y of LY3074828 
lyophilized and sol ution formulations will be assessed.  Dosing using the IVroute will 
allow the abso lute bioavailabilit y of LY3074828 to be determined.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 19
LY3074828Study I6T-MC-AMAE is being conducted in approximately 54healt hy subje cts.  The 
study  will assess relative bioavailabilit y of LY3074828 sol ution formulation in pre- filled 
1-mL syringes co mpared to lyophilized formulat ion (250 mg). Doses of 250 (2 x 1-mL
syringes) and 500 m g (4x 1-mL syringes) of LY3074828 are included in the assessment.
3.3. Benefit/Risk Assessment
Based on LY3074828 nonclinical and preliminary clinical data, there are no anticipated risks 
requi ring m onitoring bey ond those for a ty pical  humanized m onoclonal antibody  in human 
studi es.  As wi th other immunom odula tory therapies, LY3074828 may  increase the ri sk of 
developing an infect ion or m ay exacerbate an existing serious infect ion.  These may  include 
opportunist ic infect ions and react ivation of latent infect ions, such as tuberculosis (TB) and 
hepat itis B.  Subje cts will therefore be screened for hepat itis B/C, human immunodeficiency 
virus (HIV), and TB.  
Treatment -emergent ADAs have been observed in 2 of the 11 healt hy subjects that have been 
administered SC doses of LY3074828; however, titers were ≤1:160.  No c linically significant 
safet y or tol erabilit y concerns have been ident ified in pat ients or subjects to date for LY3074828 
up to the highest dose given (single 1200 -mg IV doses).  
Healthy subjects are not expected to derive any benefit from participating in studi es of 
LY3074828.  
Possible device -based risks include local effects such as pain at the injection site fro m either the 
needle or the solut ion entry  into the SC ti ssue, swelling, ery thema, bleeding, and bruising.  
Systemic effects may  include sweating, feeling faint, or fever, as a sign of infect ion.  These risks 
are mit igated by  sterile filling of the semi -finished sy ringes (SFS s), assembly of devices that 
meet regulatory  standards, training of invest igative site staff and subjects on proper i njecti on 
techniques, and monitoring of the subjects to ensure inject ions are performed properly.
More informat ion about the known and expected benefits, risks, SAEs ,and reasonably 
anticipated AEs of LY3074828 are to be found in the Invest igator’s Brochure (IB).
More informat ion about the known and expected benefits, risks, SAEs, and reasonably 
anticipated AEs of the AI is found in the device IB.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 20
LY30748284.Objectives and Endpoints
Table AMAQ .1shows the object ives and endpo ints of the study .
Table AMAQ .1. Objectives and Endpoints
Objectives Endpoints
Primary
Part A
To evaluate the PK of LY3074828 solution 
formulation after administration of 250 -mg 
doses using 2 x 1-mL and 1 x 2-mL PFS 
injections in healthy subjects.
To assess the safety andtolerability of, and 
pain associated with ,LY3074828 PFS 
administrations in healthy subjects.Part A
The primary PK endpoints will be the C max, 
AUC (0-tlast), and AUC(0-∞ ) of LY3074828.
Incidence of TEAEs.
SF-MPQ, including VAS pain score.
Part B
To compare the safety and tolerability of ,and 
pain associated with ,LY3074828 solution 
formulation after administration of 125- and 
250-mg doses using 1 -mL AI and 2 - mL AI 
SC injections with different injection speeds 
(slow and fast) in healthy subjects.Part B
Incidence of TEAEs.
SF-MPQ, including VAS pain score.
Abbreviations:  AI = autoinjector; AUC(0 -∞) = area under the concentration versus time curve from time zero to 
infinity ; AUC(0 -tlast) = area under the concentration versus time curve from time zero to time t, where t is the 
last sample with a measurable concentration; C max= maximum observed drug concentration; PFS = pre -filled 
syringe; PK = pharmacokinetic; SC = subcutaneous; SF -MPQ = Short Form McGill Pain Questionnaire; 
TEAE = treatment -emergent adverse event; VAS = visual analog scale.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 21
LY30748285.Study  Design
5.1. OverallDesign
Study  I6T-MC-AMAQ (AMAQ) is a single -center, ran domized, parallel -treatm ent, open -label, 
Phase 1 single -dose study  of LY3074828 so lution formulation in healt hy subjects.  In Part A, 
PK, safet yandtolerabili tyof, and pain associated wi th,SC dose sadministered using 1- and 
2-mL PFS injections will be evaluated.  In Part B, safet yandtolerabilit yof,and pain associated 
with,single AI inject ionsof 1-and 2 -mL that will be administered with 2 different inject ion 
speeds will be evaluated.
Screening Period ( ≤28 days):   Subjects will be eval uated for stu dy eligibilit y ≤28 days pri or to 
enrollment.
Residential Period (2 days [Part A] or 3 days [Part B] ):  
A total of approximately 72 subjects 
(approximately 36 subjects per study  Parts A and B) who fulfill the eligibilit y criteria will  be 
rando mized to 1 of 2 dosing regimen arms wit hin their assigned study  part, wi th 18subjects 
rando mized to each arm in orde r to ensure completio n of 16 subjects in each :
Part A
Reference:  250 mg LY3074828 so lution formulation, 2 x 1 -mL 125 -mg/mL PFS 
inject ionsusing an invest igational PFS targeting 5 -to 10-second inject ion time for 
each inject ion
Test 1:  250 mg LY3074828 so lution formulation, 1 x 2- mL 125 -mg/mL PFS 
inject ionusing an invest igational PFS targeting 5 -to 15-second inject ion time
Part B
Tests 2 and 3:  250 mg LY3074828 solut ion formulation, 1 x 2- mL 125 -mg/mL AI 
slow inject ion (Test 2; targeting approx imately 13-second inject ion time) and fast 
inject ion (Test 3; targeting approx imately 5-second injection t ime)using an 
investigat ional 2-mL AI
Tests 4 and 5:  125mg LY3074828 solut ion formulation, 1 x 1-mL 125 mg/mL AI 
slow inject ion (Test 4; targeting approxima tely 7-second inject ion time) and fast 
inject ion (Test 5; targeting approximately  4.5-second injection t ime) using an 
investigat ional 1-mL AI
For Part A, subjects will report to the clinical research unit (CRU) on Day  -1 and will remain at 
the CRU unt il the scheduled procedures have been completed on Day 2.  After randomizat ion to 
either a 2 x
1-mL or a 1 x 2-mL 125-mg/mL PFS dose regimen , study drug will  be administered 
by invest igative site staff by SC inject ion in the abdomen in the morning of Day 1 after an 
overnight fast.
For Part B, subjects will report to the CRU on Day - 1 and will remain at the CRU unt il the 
scheduled procedures have been completed on Day 3.  Subjects will be rando mized to receive, 
on Day s 1 and 2, either a 1 x 1- mL or a 1 x 2- mL125-mg/mL AI dose regimen.  The allocated 
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 22
LY3074828AI dose regimen will be self -administered by slow and fast SC injection (s)on consecut ive days 
(sequence rando mized ) in the abdomen after an overnight fast .  
Outpatient Follow -up Period (12 weeks):   The follow -up peri od will include outpatient visits 
for a total  of 12 weeks (Days 4, 8, 11, 15, 22, 29, 43, 57, 71, and 85 for Par t A; Days 15, 43, and 
86for Part B) following dose administrati on on Day  1to assess the PK, safet y,andtolerabilit y
of, and pain associ ated wi th,LY3074828 PFS administrations for Part A ,and to assess the safet y
andtolerabilit yof, and pain associ ated with
,LY3074828 invest igational AI admini strations for 
Part B.
Safety and tol erabilit y will  be expl ored by clinical  laboratory  tests, vi tal sign measurements, 
12-lead ECGs , recordi ng of AEs and product compl aints, physical  examinat ions/medical 
assessments, immunogenicit y, and inject ion-site assessments.  Pain assessments will be made 
using the Short Form  McGill Pain Quest ionnaire ( SF-MPQ ), whi ch includes a subject -assessed 
inject ion
-site pain visual analog scale ( VAS ).
5.2. Number of Participants
A total o f approximately  72 subjects (approximately  36 subjects per study  Parts A and B) who 
fulfill the eligibilit y criteria will  be randomized to 1 of 2 dosing regimen arms wit hin their 
assigned study  part, wi th 18subjects r andomized to each arm in order to ensure completion o f 
16subjects in each.  A subject’s study  parti cipat ion is considered as co mplete if he/she receives 
the study  drug as per the protocol requirements and completes all activit ies up to and including at 
least Day  57 for Part A or up to and including at least Day  15for Part B.  A maximum of 
4subjects per arm  per study  part may be replaced if mult iple subjects do not complete the study .
5.3. End of Study Definition
End of the study  is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) f or the last subjec t.
5.4. Scientific Rationale for Study Design
Conducting the study  in healt hy subjects mit igates the potenti al confounding effects of the 
disease state and concomitant medications in pat ients.  Healthy subjects are frequent ly used in 
the assessment of bioavailabil ity of both small and large mo lecules.
For Part A, s ingle doses of LY3074828 and the PK sampling time points have been selected to 
generate PK profiles sufficient to fulfill the study  object ives.  As the primary endpo ints for 
Part A of this study  are PK -related and are not subject to bias, it is not considered necessary  for 
this study  to be blinded.  Subjects and site staff will be aware of the administration route and 
treatm ent.
For Part B, only an evaluat ion of safet yand tolerabili tyof,and pain associ ated wi th,the 
investigat ional AI administrations is intended.  Pharm acokinet ic samples are collected only in 
conjunction with immunogenici ty samples to provide concentrations of LY3074828 toaid in the 
interpretati on of  ADA data if needed.
I6T - MC- AMAQ(b )C l in ica l  Pha rmaco logy  P ro toco l Page  23
LY3074828Fo r  P a r t  A ,  ap a r a l l e l - g roup  d e s i g n  w a s  c h o s e n  b e c a u s e  a  c r o s s o v e r  d e s i g n  i s  im p r a c ti c a l  f o r  
com p o u n d s  t h a t  h a v e  l o n g  h a l f - l i v e s ,  s u c h  a s  m o no c l on a l  an ti b o d i e s .   A d d i t i o n a l ly ,  a  c ro s sov e r  
s tudy  d e s ign  cou l d  c o n f o u n d  PK  d a t a  i f  s u b j e c t s  d e v e l o p  n e u t r a l i z i n g  ADA s .
Fo r  P ar t  B ,  a  c r o s s o v e r  d e s i g n  w a s  c h o s e n  a s  PK a n a l y s i s  i s  n o t  a n  e n d p o i n ta n d  a  r e l a t i v e l y  
s h o r t  t im e  b e tw e e n  i n j e c t i o n s  w i l l  a l l ow  a  m o r e  a c c u r a t e  c om p a r i s o n  o f  i n j e c t i o n - s i t e  p a in  by  
sub j e c t s
Mono c l on a l an t ibody  th e r apy  h a s  b e en  a s so c i a t ed  w i th  h y p e r s e n s i t i v i t y  r e a c t i o n s ,  i n c l u d i n g  
i n j e c t i o n -s i t er e a c t i on s .   Fo l l ow - u p  d e t a i l s  o n  in j e c t i on - s i t er e a c t i on s  w i l l  b e  co l l e c t ed  by  th e  
i n v e s t i g a t i v e  s i t e  r e g a r d i n g  t h e  s e v e r i t y , du r a t i o n ,  t y p e ,  a n d  tim i n g  o f  th e  s t a r t  o f  t h e  e v e n t  i n  
r e l a t i o n  t o  t h e  s t a r t  o f  s t u d y  d ru g  adm in i s t r a t i o n  i n  o r d e r  t o  f u r t h e r  c h a r a c t e r i z e  t h e s e  e v e n t s .
5 .5 .Jus t i f ica t ion  fo r  Dose
CC I
Do s e s  up  to  1200m g  w e r e  f o u n d  t o  b e  w e l l  t o l e r a t e dw h e n  a dm i n i s t e r e d  b y  IV  i n f u s i on  i n  
h e a l th y  s u b j e c t s  i n  t h e  s i n g l e - do s e  S tudy  A MAD .   S u b c u t a n e o u s  b i o a v a i l a b i l i ty  w a s  
a p p r o x im a t e l y  40%  in  S tudy AMAA .
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 24
LY30748286.Study  Population
Eligibilit y of subjects for study  enrollment will be based on the results of medical history , 
physical examinat ion, vital signs, clinical laboratory tests, and ECG.  
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening will occu r up to 28 day s prior to enrollment.  Subjects who are not enrolled within 
28days of screening may  be subjec ted to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusio n Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and/or enrollment:
[1]are overtly healt hy male or female subjects, as determined by medical history  
and physic al examinat ion
[1a]male subjects:
Men, regardless of their fertilit y status, with non -pregnant wom en of 
childbearing potential partners m ust agree to ei ther rem ain abst inent (if this 
is their preferred and usual lifest yle) or use condoms as well as one 
additional highly effect ive (l ess than 1% failure rate) method of 
contraception (such as co mbination oral contraceptives, implanted 
contraceptives ,or intrauterine devices) or effect ive method of contraception 
(such as diaphragms wit h spermicide or cervical sponges) for the durat ion 
of the study  and for 24 weeks following dosing wi th the study  drug
oMen and their partners may  choose to use a double -barrier method 
of contracepti on.(Barri er protecti on m ethods wi thout concomi tant 
use of a spermicide are not an effect ive or acceptable method of 
contraception. Thus, each barrier method must include use of a 
spermicide. It should be noted, however, that the use of male and 
female condo ms as a double -barrier m ethod is not considered 
acceptable due to the high failure rate when these barrier methods 
are combined)
oPeriodic abst inence (e.g., calendar, ovulat ion, symptothermal, 
post-ovulation methods), decl aration of  abstinence just for the 
durati on of  a trial , and wi thdrawal  are not acceptable methods of 
contraception
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 25
LY3074828Men wi th pregnant partners should use condoms during intercourse for the 
durati on of  the study  and for 24 weeks following dosing wit h the study  drug
Men should refrain fro m sperm  donat ion for the durati on of  the study  and 
for 24 weeks following dosing wi th the study  drug
Men who are in exclusively same -sex rel ationships (as their preferred and 
usual lifest yle) are not required to use contraception
[1b] female subjects:
All female subjects must test negative for pregnancy  prior to ini tiation of 
treatm ent as indicated by  a negative serum pregnancy test at the screening 
visit fo llowed by  a negat ive serum pregnancy test within 24 hours prior to 
exposure
Women of childbearing potential who are abstinent (if this is co mplete 
abstinence, as their preferred and usua l lifest yle) or in a same -sex 
relationship (as part of their preferred and usual lifest yle) must agree to 
either rem ain abst inent or stay in a same -sex rel ationship wit hout sexual 
relationships wit h males. Periodic abst inence (e.g., calendar, ovulat ion, 
symptothermal, post -ovulation methods), decl aration of abst inence just for 
the duration of a trial, and wit hdrawal are not acceptable methods of 
contraception
Otherwi se, women of childbearing potential part icipating must agree to use 
one highly effect ive method(less than 1% failure rate) of contraception, or 
a combinat ion of 2effective methods of contraceptio n (for12 weeks
following dosing wit h the study  drug)
oEither one hi ghly effect ive method of contraception (such as 
combinat ion oral  contraceptives, implanted contraceptives ,or 
intrauterine device) or a combinat ion of 2 effect ive methods of 
contraception (such as male or female condo ms with spermicide, 
diaphragms wit h spermicide ,or cervical sponges) will be used. The 
subject may choose to use a double -barrier method of contracepti on. 
Barri er protecti on m ethods wi thout concomi tant use of a spermicide 
are not a reliable or acceptable method. Thus, each barrier method 
must include use of a spermicide. It should be noted that the use of 
male and femal e condom s as a double -barri er method is not 
considered acceptable due to the high failure rate when these 
methods are combined
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 26
LY3074828Women not of childbearing potential may participate and include those who 
are: 
oinfertile due to surgical sterilizat ion (hysterec tomy, bilateral 
oophorectomy , or tubal  ligation)orcongenital anomaly such as 
mullerian agenesis; or 
opostmenopausal –defined as eit her:
A wo man at l east 50 years of age with an intact uterus, not 
on hormone therapy , who has had either:
cessat ion of mens es for at l east 1 y ear;or 
at least 6 m onths of spontaneous amenorrhea with a 
follicle -stimulat ing horm one >40 m IU/mL; or 
A wo man 55 or older not on hormone therapy , who has had 
at least 6 m onths of spontaneous amenorrhea; or 
A wo man at l east 55 years o f age wi th a diagnosi s of 
menopause prior to starti ng horm one-replacement therapy
[2] are between 18 and65 years of age, inclusive, at time of screening
[3] have a body  mass index (BMI) of 18.0 to 32.0 kg/m 2, inclusive, at time of 
screening
[4] have clinical laboratory  test resul ts wi thin norm al reference range for the 
investigat ive site, or results with acceptable deviat ions that are judged to be 
not clinically significant by  the invest igator
[5] have venous access sufficient to allow for blood sampling as per the protocol
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[7] are able and willing to give signed informed consent
6.2. Exclusion Criteria
Subjects will be excluded from study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[8] are invest igative site personnel direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, biological or
legal guardian, child, or sibling
[9] are Lilly  empl oyees or em ployees o f Covance
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 27
LY3074828[10] are currently enrolled in a clinical  study  involving an invest igational product 
(IP) or any  other ty pe of medical research judged not to be scient ifically or 
medically compat ible with this study
[11] have participated in a clinical trial invo lving an IP within 30 days or 
5half-lives (whichever is lo nger) prior to screening.  If the clinical trial 
involved treatment with bio logic agents (such as monoclonal ant ibodies, 
including m arketed drugs), at least 3 mo nths or 5 half -lives (whichever is 
longer) should have elapsed prior to Day  1
[12] have previously completed or withdrawn fro m this study  or any  other study  
investigat ing LY3074828, and have previously received the IP
[13] have known allergies to LY3074828, related compounds, or any  com ponents 
of the form ulation, or hi story  of significant atopy
[14] have an abnormalit y in the 12 -lead ECG that, in the opinion o f the 
investigator, increases the risks associated with parti cipat ing in the study
[15] have an abnormal blood pressure as determined by the investigator
[16] have a history  or presence of cardiovascular, respiratory , hepat ic, renal, 
gastrointestinal, endocrine, hematological, or neurological disorders capable 
of significant ly altering the absorption, metabolism, or eliminat ion of drugs; 
of const ituting a risk when taking the IP; or of interfering with the 
interpretati on of  data
[17] have known or ongoing psychiatric disorders deemed clinically  significant by  
the inv estigator
[18] regul arly use known drugs of abuse and/or show posit ive findings on drug 
screening
[19] show evidence of HIV infection and/or posit ive HIV ant ibodies
[20] show evidence of hepatit is C and/or positive hepat itis C ant ibody
[21] show evidence o f hepati tis B, and/or posit ive hepatit is B surface ant igen, 
and/or hepatit is B core antibody 
[22] are wom en who are lactating
[23] have used or intend to use over -the-counter or prescript ion medications, 
including herbal medicat ions, within 14 days pri or to dosing and for the 
durati on of  the study .  Stable doses of oral contraceptive or 
horm one-replacement therapy  are permi tted, at the discret ion of the 
investigator
[24] have donated blood of more than 500 mL within 1 month prior to screening 
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 28
LY3074828[25] have an average weekly  alcohol  intake that exceeds 21 units per week (males) 
and 14 units per week (females), have a posit ive test for ethano l, or are 
unwilling to abide by the alcohol restrict ions described in Sect ion 6.3.2 (1 unit 
= 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of 
distilled spirits)
[26] have a tobacco consumpt ion of more than 10 cigarettes per day  (or 
equivalent), are unwilling to refrain fro m smoking for approximately  1 hour 
prior to each ECG and vital sign measurements during the study , or who are 
unwilling to abide by the CRU smoking guidelines described in Sect ion 6.3.2
[27] have had symptomat ic herpes zoster within 3 mo nths of screening
[28] show evidence of active or latent TB, as documented by medical history , 
examinat ion, and TB testing (negat ive [not inde terminate] 
Quant iFERON ®-TB Gol d test); or have had househo ld contact with a person 
with active TB, unless appropriate and documented prophylaxis treatment has 
been given .  Subj ects wi th any history  of active TB are excluded from the 
study , regardl ess of previous or current TB treatments
[29] have received live vaccine(s), including attenuated live vaccines and those 
administered intranasally, wit hin 8 weeks of screening, or intend to during the 
study
[30] have been treated with steroids within 1 month of screening, or intend to 
during the study
[31] are immunocompro mised
[32] have received treatment with bio logic agents (such as monoclonal ant ibodies) 
for a medical condit ion within 3 m onths or 5 half -lives (whichever is longer) 
prior to Day  1
[33] have sig nificant allergies to humanized monoclonal antibodies 
[34] have clinically  significant m ultiple or severe drug allergies, or intolerance to 
topical corti costeroi ds, or severe posttreatment hypersensit ivity react ions 
(including, but not limited to, ery thema mul tiforme major, linear 
immunogl obulin A dermatosis, toxic epidermal necrolysis, or exfo liative 
derm atitis)
[35] have had lympho ma, leukemia, or any  malignancy  within the past 5 years 
except for basal cell or squamous epithelial carcinomas of the skin t hat have 
been resected with no evidence of metastatic disease for 3 years
[36] have had breast cancer within the past 10 y ears
[37]have excessive tattoos over the abdo menthat would interfere with 
inject ion-site assessments
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 29
LY3074828[38]in the opinio n of the invest igator, are unsuitable for inclusion in the study
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects m ay undergo m edical  assessments and review of compliance with 
requi rements before continuing in the study .  
6.3.1. Meals and Dietary Rest rictions
Subjects willfast overnight for at least 8 hours before dosing (water is permitted).  Standard 
meals will be provided at all other times while subjects are resident at the CRU, as per the 
CRU’s policy.
6.3.2. Caffeine, Alcohol, and Tobacco
Subjects willnot consume caffeinated beverages (decaffeinated beverages are permitted) while 
at the CRU, and for 12 hours prior to admissio n to the CRU.  At other times during the outpatient 
period, subj ects will be allowed to maintain their regular caffeine consumpt ion.
Alcoho l consumpt ion is not permitted while at the CRU, and for 12 hours prior to each study 
visit.  At other times, alcoho l consumpt ion should be limited to 2 units per day (1 unit = 12 oz or 
360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of d istilled spirits).
Subjects who smoke will be advised to not increase their consumpt ion of tobacco products 
during the study .  Subj ects will be asked to refrain from smoking for approximately  1hour pri or 
to each ECG and vital sign measurements, and to abi de by  the CRU sm oking guidelines.
6.3.3. Activity
Subjects will be advised to maintain their regular levels o f physical act ivity/exercise during the 
study , but to refrain from strenuous activit y from 24hours prior to each visit and 48 hours prior 
to any  visit where creatine phosphokinase testing will occur (Day  
-1, Day  8, and Day  29in 
Part A,and Day -1, Day  15, and Day  43in Part B ).  While certain study procedures are in 
progress at the site, subjects may be required to remain recumbent or sitting.
6.3.4. Blood and Plasma Donation
Subjects will not donate blood or plasma for 12 weeks following dosing wit h the study  drug.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
re-screened.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 30
LY30748287.Dosing Regimens
7.1. Dosing Regimens Administ ered
This study  eval uates the PK, safet y,and tolerabili tyof, and pain associated with , LY3074828 
solution formulation SC dose administered by investigat ional site staff using 2 x 1-mL and 
1 x
2-mL PFS injections (Part A);and co mpares the safet yandtolerabili tyof,and pain 
associ ated wi th, 1 x 1 -mL and 1 x 2-mL AI inject ions self-administered with 2 different inject ion 
speeds (Part B).
Using the invest igational 2-mL AI, the targeted injection duration will be approximately 
13seconds for slow inject ion rate and approximately 5 seconds for fast inject ion rate.  Using the
investigat ional1-mL AI, the targeted inject ion duration will be approximately 7 seconds for slow 
inject ion rate and approximately 4.5 seconds for fast inject ion rate.  Manual inject ions using the 
investigat ional PFS shoul d target an injection duration of about 5to 10 seconds for 1-mL PFS for 
each inject ionand about 5to 15seconds for 2-mL PFS, to approximate the inject ion time range 
for AIs.  Approximate i nject ion duration sfor AIs and PFSs will be obtained u
sing a calibrated 
stopwatch and recorded in the electroni c case report form ( eCRF ).  
Drug and device accountabilit y records will be maintained by  the si te pharmacy .
Table AMAQ. 2andTable AMAQ. 3show the dosing regimens for Part A and Part B, 
respectively .
Table AMAQ. 2. Dosing Regimens Administered –Part A
Dosing RegimenPFS
(250 mg)PFS
(250 mg)
Reference/test Reference Test 1
Product LY3074828 LY3074828
Dose 250 mg 250 mg
Concentration 125 mg/mL 125 mg/mL
Injection volumes2 × 1 mL
(2 mL total)1 × 2 mL
(2 mL total)
Number of injections 2 1
Injection rate 5 to 10 seconds 5 to 15 seconds
Formulation and presentation Solution in a PFS Solution in a PFS
Abbreviations:  PFS = pre -filled syringe.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 31
LY3074828Table AMAQ. 3. Dosing Regimens Administered –Part B
Dosing Regimen2-mL AI
(250 mg)1-mL AI
(125 mg)
Reference/test Test 2 and Test 3 Test 4 and Test 5
Product LY3074828 LY3074828
Dose 250 mg 125mg
Concentration 125 mg/mL 125 mg/mL
Injection volumes1 × 2 mL
(2 mL total)1× 1 mL
(1mL total)
Number of injections 1 1
Injection rateApproximately 13seconds (Test 2)
Approximately 5 seconds (Test 3)Approximately 7seconds (Test 4)
Approximately 4.5 seconds (Test 5)
Formulation and presentation Solution in an AI Solution in an AI
Abbreviations:  AI = autoinjector.
Invest igational AIs will be assembled at the site by Lilly Delivery and Device Research and 
Development engineers.  Device Development Qualit y Assurance will inspect the assembled 
investigat ional devices on si te to ensure basic good manufacturing practice (GMP) guidelines are
met, and that assembly is performed as per GMP procedures, prior to use in the clinical trial.  
The invest igational PFSs containing LY3074828 will be supplied by  Lilly  fully assembled.
Adjustments to the device (such as changing the spring) will be based on injecti on durati on and 
tolerabilit y/AEs (pain, bleeding, bruising, leakage, induration, swelling, pruritus, and 
erythema/redness) , and will be performed on site .  Device i ssues that resul t in AEs will be 
reported as product qualit y complaints (PCs) .
Allinjecti ons, whether administered by  PFS or AI, will be given into the lower quadrant of the 
abdo men, with site staff or subject sel ecting left or ri ght quadrant when a single inject ion is 
being given . For administrations requiring 2 injectio ns, inject ions will be given into separate 
lower quadrants (right and left). Invest igational product administered using PFS will be 
administered to subjects on -site by  designated t rained clinical site personnel.   Invest igational 
product administered using AI will be self -administered by  subjects on -site after receiving 
instructi on from trained clinical site personnel.
Further informat ion regarding SC administration will be included in the device Instructions for 
Use(IFU) for the PFS and in the device IB (which contains IFU) for the AI .
In some cases, the site may destroy  the m aterial if, during the invest igative site select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical trial materials.  
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 32
LY30748287.1.1. Packaging and Labeling
LY3074828 will be supplied by the sponsor or its designee in accordance with current GMP, and 
labeled according to the coun try’s regulatory  requirem ents. The following products will be 
supplied by  Lilly :
pre-assembled invest igational LY3074828 PFSs, 1- mLand 2 -mL
LY3074828 (solut ion for inject ion) SFS 
Each SFS will be supplied as a 1- or 2-mLsingle -use sy ringe designed to deliver LY3074828 
125mg/mL.  Members of Lilly  Delivery and Device Research and Development will attend the 
study  site and assemble t he SFS andappropri ate device components ,to form the investi gational 
AIs. 
Each invest igational device will be individually  ident ified and labeled according to US 
regul atory  requi rements for investigational device s.
7.2. Method of Treatment Assignment
Subjects will be rando mized within 1study  part (Part A or Part B)to 1 of 2 dosing regimen arms 
(Table AMAQ. 2and Table AMAQ. 3
).  In addit ion, the sequence of injections on Days 1 and 2
(fast/sl ow versus slow /fast) for subjects participat ing in Part B will be randomized. 
Randomization wil l be perform ed using a com puter -generated randomizat ion schedule.
7.2.1. Selection and Timing of Doses
The actual  time of all dose administrations will be recorded in the subject’s eCRF.
7.3. Blinding
This is an open -label study ;however ,subjects in Part B will not be informed as to whether the
AI is fast or slow inject ion speed .
7.4. Dose Modification
Dose adjust ments are not permitted in this study .
7.5. Preparation/Handling/Storage/Accountability
The IPs for this study  will be:
LY3074828 in an investigational PFS
LY3074828 in an SFS incorporated into a n investigational AI
Invest igational product will be stored refrigerated at 2°C to 8°C (36°F to 46°F) in its original 
carton to protect from light.  Invest igational product should not be frozen or shaken.  Sites will 
be required to monitor temperature of t he on -site storage condi tions of  the IP.  The investigator 
or desi gnee m ust confirm  appropriate tem perature condi tions have been maintained, as 
communicated by  the sponsor, during transit for all IP received and ensure any  discrepancies are 
reported and resolved before use of the study  treatment.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 33
LY3074828The SFSs assembled into AIs containing LY3074828 and the PFSs containing LY3074828 
shoul d be allo wed to warm  to room  temperature for at l east 30 minutes before use. 
Parts to be used for the assembly of AIs may  be stored at room temperature.
Only participants enro lled in the study  may receive IP or study  materials, and only authorized 
site staff may supply IP.  All IP should be stored in an environmentally -controlled and monitored 
(manual  or autom ated) area i n accordance wi th the labeled storage condit ions wit h access limited 
to the invest igator and authorized site staff.
The invest igator is responsible for study treatment accountabilit y, reconciliat ion, and record 
maintenance (such as receipt, reconciliat ion, and final disposit ion records).
7.6. Treatment Compliance
The IPwill be administered at the clinical site, and documentation of treatment administration 
will occur at the site.
7.7. Concomitant Therapy
Over -the-counter or prescript ion medications, including herbal med ication, are not permitted 
within 14 days prior to dosing and throughout the study .  However, stable doses of oral 
contraceptive or hormone -replacement therapy  are permi tted at the discretion of the invest igator.
Paracetamo l/acetaminophen (up to 2 g/day) is permitted at the discret ion of the invest igator.  
Addit ional drugs are to be avo ided during the study, unless required to treat an AE.
If the need for concomitant medicat ion arises, inclusi on or continuat ion of the subject may be at 
the discret ion of th e invest igator after consultation with a Lilly clinical pharmaco logist (CP) or 
clinical research physician (CRP) .  Any addit ional medicat ion used during the course of the 
study  must be docum ented.
7.8. Treatment after the End of the Study
This sect ion is not ap plicable for this study.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 34
LY30748288.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
Randomized subjects who discont inue the study prematurely for any reason shoul d com plete the 
early  discontinuat ion (ED) pr ocedures performed as shown in the Schedule of Activities
(Secti on2).  The reason for, and the date of discontinuat ion, will be co llected for all subjects.
8.1.1. Discontinuation of Inadvertently Enro lled Subjects
If the sponsor or invest igator ident ifies a subject who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CPor CRP and the invest igator 
to determine if the subject may  cont inue in the study .  If a subject is inadvertent ly enro lled into 
Part B and this is discover edprior to the scheduled administration of the second dose, the second
dose would not be administered.  Any subjects that are inadvertent ly enro lled subjects will be 
followed for safet y.
8.2. Discontinuation from the Study
Subjects will be discont inued in the fo llowing ci rcum stances:
Enrollment in any other clinical study  involving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice
The invest igator decides that the subject should be discontinued from the study
The subject requests to be withdrawn fro m the study
Subjects who discont inue the study  early  will have ED pr ocedures performed as shown in the 
Schedule of Act ivities(Secti on
 2).
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 35
LY30748289.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the clinical laboratory  tests that will be performed for this study .
Appendix 5 provi des a summary  of the m aximum  number and vol ume of invasive samples, for 
all sampling, during the study .
The specificat ions in this protocol for the timings of safet y and sample co llection are given as 
targets to be achieved wit hin reasonable limits.  Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion.  The scheduled t ime po ints may be subject to minor 
alterati ons; however, the actual time must be correctly  recorded in the eCRF.  Late collection 
outsi de the st ipulated time allowances or failure to obtain samples due to clinical issues, such as 
probl ems wi th equipment, venous access, or subject defaulting on a scheduled procedure, will 
not be considered as protocol deviations but the site will st ill be requi red to notify  the sponsor in 
writing via a file- note.
Unless otherwise stated in subsect ions below, all samples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
Investigators must docume nt their review of each laboratory  safety  report.
9.1. Efficacy Assessments
This sect ion is not applicable for this study .
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study 
and for alerting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Invest igators m ust docum ent thei r review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the IPor the study , 
or that caused the subject to discontinue the IPbefore complet ing the study .  The subject should 
be followed unt il the event resolves, stabilizes wit h appropriate diagnostic evaluat ion, or i s 
reasonably  explained.  The frequency  of follow-up evaluat ions of t he AE is left to the discret ion 
of the invest igator.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 36
LY3074828After the informed consent form is signed, study  site personnel will record, via eCRF, the 
occurrence and nature of each subject’s preexist ing conditions.  Addit ionally , site personnel will  
record any  change in the condit ion(s) and the occurrence and nature of any  AEs.  
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account
concomitant treatment or pathologies.  
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the IP, 
study  device, and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying m edical condit ion has 
worsened during the course of the study .
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immedia te risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but may jeopardize the subject or may require inte rventi on to prevent 
one of the other outcomes listed in the definit ion above
when a condit ion related to the invest igational device (PFS or AI) necessitates medical or 
surgi cal interventi on to precl ude ei ther perm anent impai rment of  a body  function or 
perm anent dam age to a body  structure, the seri ous outcom e of “requi red intervent ion” 
will be assigned
Study  site personnel  must al ert the Lilly  CRP /CP, or its desi gnee, of  any SAE as soon as 
practi cally  possible.
Addit ionally , study  site personnel  must al ert Lilly Global Patient Safet y, or its desi gnee, of any  
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information.  
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting to the 
sponsor begins after the subjec t has signed informed consent and has received IP.  However, if 
an SAE occurs after signing informed consent, but prior to receiving IPAND is considered 
reasonably  possibly  related to a study  procedure then it MUST be reported.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 37
LY3074828Invest igators are not oblig ated to actively  seek AEs or SAEs in subjects once they  have 
discontinued fro m and/or com pleted the study  (the subject summary eCRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .  
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported following the SAE 
process to collect data on the outcome for both mother and fetus.
9.2.1.1. Adverse Device Effects
Any AE believed to be related to an issue wit h the investigat ional device ( AI) or to the use of the 
study  device ( PFS)is considered an adverse device event .  These events m ust be cl early  
indicated as such in the eCRF, and reported to the sponsor .  A PCshoul d also be reported .
For the purpose of this prot ocol, “unant icipated” adverse device effect means any  serious adverse 
event alleged to be associated or related to the device, and which has been confirmed as such by  
the sponsor .  The SAE relatedness must be clearly indicated as such in the eCRF, and repo rted to 
the sponsor within 24 hours of site knowledge o f the event.   A PCshoul d also be reported.
9.2.1.2. Adverse Events of Special Interest
The fo llowing AEs of special interest will be used to determine the safet y and tol erabilit y of 
LY3074828 inject ions admini stered by  either investi gational PFS or invest igational AI in this 
clinical study .
Adverse events of special interest for LY3074828 are:
infect ion
inject ion-site reacti ons
allergic /hypersensi tivity react ions
If infections, inject ion-site reacti ons, or allergic/hypersensit ivity react ions are reported, sites will 
provi de details on these events as instructed on the eCRF. Invest igators will also educate 
subjects about the symptoms of allergic/hypersensitivit y react ions and will provide instructions 
on dea ling with these react ions. A blood sample will be co llected when possible for any subject 
who experiences an AE of allergic/hypersensit ivity reacti on during the study .
9.2.1.3. Suspected Unexpected Serious Adverse Reactions 
Suspected unexp ected serious adverse re actions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to IPor procedure.  Lilly  has procedures 
that will be fo llowed for the recording and expedit ed reporting of SUSARs that are consistent 
with global regulat ions and the associated detailed guidances.
9.2.1.4. Adverse Event Monitor ing with a Systematic Questionnaire
Befor e administering the SF -MPQ, study  site personnel will quest ion the subject about any  
change in the preexist ingcondi tion(s) and the occurrence and nature of any  AEs.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 38
LY3074828Inject ion-site assessment at the scheduled protocol time points will not be double reporte d in the 
AE form, but will be captured in the eCRF.
Only serious AEs elicited through the SF -MPQ are to be recorded as AEs via electronic data 
entry  and reported to Lilly  or its desi gnee wi thin 24 hours as SAEs.
Unsolicited AEs (e .g., headache, redness rep orted by  subjects during the follow -up peri od) will  
be reported in the AE form.
9.2.2. Complaint Handling
Lilly co llects PCs on IPs and drug delivery systems used in clinical trials in order to ensure the 
safet y of study  participants, m onitor quali ty, and to facilitate process and product improvements.
Subjects should be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th theIPor drug delivery system so that the si tuation can be assessed.   
A PFS or AI that is associated with a product quality issue or complaint must be returned to 
Lilly.
The invest igator or his/he r designee is responsible for handling the following aspects of the PC
process in accordance with the instructions provided for this study :
recordi ng a complete descript ion of the PCreported and any associated AEs using the 
study -specific co mplaint form s provi ded for this purpose,
faxing the completed Product Complaint Form wit hin 24 hours to Lilly or its designee.
If the invest igator is asked to re turn the product for invest igation, he/she will return a copy  of the 
Product Complaint Form with the product.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of LY3074828 is considered any dose higher than the 
dose assigned through rando mization.
There i s no specific antidote for LY3074828.  In the event of an overdose, the subject should 
receive appropriate supportive care and any AEs should be documented.
Refer to the study  drug IB for further details.
9.4. Safety
9.4.1. Laboratory Tests
For each subject, clinical laboratory  tests detailed in
 Appendix 2 shoul d be conducted according 
to the Schedule of Act ivities (Section 2). 
Lilly or i ts desi gnee will  provide the investi gator wi th the resul ts of laboratory  tests analyzed by  
a central  vendor, if a central vendor is used for the study .
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 39
LY30748289.4.2. Vital Signs
For each subject, vital sign measurements (blood pressure, pulse rate, and temperature) should be 
conducted according to the Schedule of Activit ies (Secti on 2).  Addit ional vital signs may be 
measured during the study  if warranted.
Blood pressure and pulse rate should be measured after at least 5 minutes supine.
Unscheduled orthostatic vital signs shoul d be assessed where considered appropriate by  the 
investigator.  If orthostatic measurements are required, subjects should be supine for at least 
5minutes and stand for at least 3 minutes.  If the subject feels unable to stand, supine vital signs 
only will be recorded.  
9.4.3. Electrocardiograms
For each subject, a single 12 -lead digital ECG will be collected according to the Schedule of 
Activities (Section 2
).  Electrocardi ograms m ust be recorded before collecting any  blood f or 
safet y or PK tests.   Subjects must be supine for at least 5 minutes before ECG collection and 
remain supine but awake during ECG collection.  Electrocardiograms may be obtained at 
additional times,when deemed clinically necessary by the invest igator.   All ECGs recorded 
shoul d be stored at the invest igational site.
Electrocardiograms will be interpreted by  the investi gator or qualified designee at the site as 
soon after the time of ECG collect ion as possible, and ideally while the subject is st ill present, to 
determine whether the subject meets entry  criteria at the rel evant visit(s) and for immediate 
subject management, should any  clinically rel evant findings be i
dentified.  
Ifa clinically significant finding is ident ified (including, but not limited to, changes in 
QT/corrected QT interval from baseline) after enrollment, the invest igator will determine if the 
subject can continue in the study .  The invest igator, or qualified d esignee, is responsible for 
determining if any change in subject management is needed, and must document his/her review 
of the ECG printed at the time of co llection.
Any clinically  significant findings from ECGs that result in a diagnosis and that occur af ter the 
subject receives the first dose of the IPshould be reported to Lilly, or its designee, as an AE via 
eCRF.
9.4.4. Other Tests
9.4.4.1. Tuberculosis Testing
Subjects will be tested as indicated in the Schedule of Act ivities (Section 2) for evidence of 
active or latent TB using the QuantiFERON -TB Gol d test.  If the test is indeterminate, 1 retest i s 
allowed.  If the retest is indeterminate, the subject will be excluded fro m the study .
Subjects who have had househo ld contact with a person with active TB must be excluded unless 
appropriate and documented prophylaxis treatment for TB has been completed
.
Subjects with any history  of active TB are excluded fro m the study , regardl ess of previous or 
current TB treatments.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 40
LY30748289.4.4.2. Injection Instructions
Prior to the PFS or AIinject ion, the invest igator or his/her designee will prepare the subject’s 
skin.  The inject ions will be given according to the instructions provided by the sponsor.  
Pre-filled syringe inject ions into the abdo men will be administered by  invest igative site staff.  
All subjects will receive training on how to use the AI to self -administer into the abdomen.  The 
investigator or his/her designee will answer any questions the subject may have and will 
demonstrate the steps required for inject ion according to the IFU.  Subjects will be monitored 
while using the AI to ensure successful self -injections.  Invest igative site staff who observe the 
subject’s self -inject ion with the AI will fill out the AI Use Assessment Questionnaire.  All study  
inject ion sites will be marked using a template for size and wit h a surgical marker in order to 
ident ify study inject ion sites for later assessme nts.
9.4.4.3. Injection Speed Assessments and Video Recording
Inject ion duration will be measured by a calibrated stopwatch by  qualified trained study  staff.  
For Part A, the duration of inject ionfor the PFS s will be defined as the time between when the 
plunger rod is pressed down andwhen all  of the LY3074828 solut ion is injected.  For Part B, the 
durati on of  inject ion for the AIs will be defined as the time between the first audible click after 
the inject ion button is pressed and the last audible click, which i ndicates that the needle has 
retracted and the inject ion is complete.  
For Part B, a video recorder will be used to record the AIinject ion site and the device as it is 
being used. The video recordings may be examined to explore device funct ionality. The 
subject ’s face, voice, orident ifiable markings will not be video recorded. The video recording 
will be ident ified by the subject number. The video data will be managed by the sponsor and 
securely  stored electronically in the sponsor ’s network. Furthe r analysis of the video recordings 
may be performed by  qualified sponsor personnel after com pletion of the study .
9.4.4.4. Injection- siteAssessments
While the SF -MPQ will be administered to capture data for pain on inject ion, other inject ion-site 
reacti onswill be captured in the subjects’ eCRF as AEs (including erythema, indurat ion, 
categori cal pain, pruritus, and edem a).  
9.4.4.5. Bleeding Assessment
All injecti on si tes will  be observed at the times indicated in the Schedule of Act ivities (Section 2) 
by the investigator or designee, and the presence of visible bleeding will be recorded on the 
eCRF.  A bandage may be placed on the inject ion site after assessm ent.
9.4.4.6. Injection- sitePain
9.4.4.6.1. Short Form McGill Pain Questionnaire
Acute pain fro m SC inject ion will be assessed using the 15 -item short form  of the SF -MPQ 
(Melzack 1987
) modified to meet the purpose of the study  at times specified in the Schedule of 
Activities (Section 2
).
As part of the SF -MPQ, pain measurements will be quan tified using the 100- mm validated VAS 
for all subjects, whether or not they  report inject ion pain .  
The VAS is a well -validated tool
(Williamso n and Hoggart 2005) to assess inject ion-site pain ; it ispresented as a 100 -mm line 
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 41
LY3074828anchored by  verbal descriptor s, usually “no pain” and “worst possible pain.”  The subject will be 
asked to rate any  pain on a scale of 0 to 100 mm on the line immediately (approximately wit hin 
5minutes) following the start of the inject ion and at the time points listed in the Schedul eof 
Activities(Secti on 2).
For 1 -mL PFS, assessments are to be completed on the first of the 2 inject ions only.
9.4.5. Safety Monitoring
The Lilly CPor CRP /scientist will mo nitor safet y data throughout the course of the st udy.
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly CPor 
CRP will periodic ally review the fo llowing data:
trends in safety  data
laboratory  analy tes
AEs,including monitoring of incidence of any nature of any infect ions, and inject ion-site 
reacti ons
PCs
When appropriate, the Lilly CPor CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y (GPS) therapeuti c area physician , GPS devi ce phy sician, or GPS clinical research 
scientist.
9.4.5.1. Hepatic Safety
If a study  subject experiences elevated alanine aminotransferase (ALT) ≥3× upper limit of 
norm al (ULN), al kaline phosphatase (ALP) ≥2× ULN, or elevated total bilirubin (TBL) 
≥2×ULN, liver tests ( Appendix 4 ) shoul d be repeated wi thin 3 to 5 days including ALT, 
aspartate aminotransferase, ALP, TBL, direct bilirubin, gamma -
glutamyl transferase, and 
creatine phospho kinase to confirm the abnormalit y and to determine if it is increasing or 
decreasing.  I f the abnormalit y persists or worsens, clinical and laboratory  monitoring shoul d be 
initiated by  the invest igator based on consultation with the Lilly CPor CRP .  Moni toring shoul d 
continue until levels normalize and/or are returning to approximate baseline levels. 
Addit ional safet y data should be co llected if 1 or more of the following condit ions occur:  
elevation of serum  ALT to ≥5× ULN on 2 or more consecut ive blood tests
elevated serum  TBL to ≥2× ULN (except for cases of known Gilbert’s syndrome)
elevation of serum  ALP to ≥2× ULN on 2 or more consecut ive blood tests 
hepat ic event considered to be an SAE
9.4.5.2. Monitoring of Hypersensitivity Reactions
There i s a ri sk of systemic hypersensit ivity react ions wit h any  biological  agent, including acute 
anaphylaxis and delayed hypersensit ivities to LY3074828.  Symptoms and signs that may occur 
as part of these hypersensit ivity react ions include, but are not limited to:  f ever, chills, j oint and 
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 42
LY3074828muscle pain, rash, itching, urticaria, dizziness, headache, throat irritation, and shortness of 
breath.  Less co mmo nly, life -threatening anaphylactic react ions may occur, which may include 
vascular collapse and/or respiratory  com promise.
All subjects will be closely mo nitored for si gns and symptom s of hypersensit ivity react ions 
following administration of the study  drug, and appropriate medical care should be provided .  
Hypersen sitivity react ions will be evaluated by examinat ion of T EAEs and SAEs, and through 
the use of a fo llow-up form which will be com pleted by  the invest igator.  Potential 
hypersensit ivity events will be evaluated by a Lilly CRP based on accepted criteria ( Sampson et 
al. 2006 ). 
9.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities (Secti on 2), venous blood samples 
of approximately  2mL each will be co llected to determine the serum concentrati ons of 
LY3074828 for Parts A and B .  A maximum o f 3 sam ples m ay be collected at addit ional time 
points during the study  if warranted and agreed upon between both the invest igator and sponsor.  
Instructi ons for the collect ion and handling of bloo d sam ples will  be provi ded by the sponsor .  
The actual  date and time (24
-hour clock time) of each sampling will be recorded.
Pharmacokinet ic samples will be co llected in both Part A and Part B; however, PK statist ical 
analyses will only be performed for Pa rt A.  Samples from Part B will be stored and will only be 
sent for bioanalysis at a later date based on immunogenicit y or safet y resul ts from Part B of the 
study .
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .  Concentrations of LY3074828 will be assayed using a validated 
enzyme- linked immunosorbent assay.  
Bioanaly tical samples collected to m easure IPconcentrations will be retained for a maximum o f 
1 year fo llowing last subject visit for the study .  
9.6. Pharmacodynamics
9.6.1. Immunogenicity Assessments
Blood sam ples f or immunogenicit y testing will  be collected to determine ant ibody  producti on 
against LY3074828 , as specified in the Schedule of Act ivities (Secti on 2)for Parts A and B .  
Addit ional samples may  be collected if there is a possibilit y that an AE is immunol ogically  
mediated. If addit ional immunogenici ty testing samples are taken, m atching PK sample 
collect ions will also be required. Immunogenicit y will be assessed by  a validated assay designed 
to detect ADAs in the presence of the IP.  Antibodies may be further characterized and/or 
evaluated for their abilit y to neutralize the activit y of the IP.  
A risk -based approach will be used to monitor subjects who develop TE -ADAs during and 
following treatm ent wi th LY3074828.  Treatment -emergent ADAs are defined as eit her a 2-fold 
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 43
LY3074828increase in titer (i .e.,1:20) above the minimum required dilut ion (1:10) if no ADAs were 
detected at baseline (predose), or a 4- fold or greater increase in t iter over baseline for subjects 
that are ADA -positive at b aseline.  LY3074828 is a monoclonal ant ibody  that binds to p19 of 
IL-23, and there is no unique/non -redundant endogenous protein counterpart, greatly  minimizing 
the risk of cross -reactive ADA.  Any potential risks of ADA development fo llowing this 
single-dose tri al woul d be dependent on LY3074828 exposure outside of this clinical trial.  The 
largest potential risk would be react ion upon subsequent drug exposure that could range in 
severit y from mild local inject ion-site reacti onsto systemic anaphylaxis and /or systemic immune 
complex disease (Arthus -react ion).  These potential risks would likely  be associ ated wi th higher 
serum  concentrati ons of ADA.  
Given that the subjects have only a single exposure to LY3074828 in Part A, and only 2 doses 
over an approxi mately 24 -hour peri od in Part B , any ADA response is ant icipated to peak and 
then diminish due to lack o f additional exposures.  Subjects will have ADA sampling at baseline 
(predose) and Days15, 29, 57, and 85 in Part A , and at baseline (predose) and Days 15, 43, and 
86in Part B .  Subjects that are observed to have a titer greater than 1:1000 ,or non-decreasing 
titers that m eet the definit ion of TE -ADA ,will
be requested to return every  3months after the 
last sample to have fo llow-up ADA samples tested until the titer has returned to within 1 titer of 
their baseline or i s clearly trending back to the baseline titer.  The rationale for the definit ions of 
both TE -ADA and return to baseline is based on the premise that a 1 -titer change m ay resul t 
from expec ted assay vari ability. 
Subjects followed for at least 1 y ear since last dose who have not returned to baseline, as defined 
above, will be assessed for safet y concerns and, if no clinical sequelae are recognized by  the 
clinical team, no further fo llow-up w ill be required.  Subjects who have clinical sequelae that are 
considered potentially  related to the presence of TE -ADA may also be asked to return for 
additional follow-up testi ng.  
Samples will  be retained for a m aximum  of 15 y ears after the last subjec t visi t, or f or a shorter 
period if local  regulat ions and the inst itutional review board (IRB) allow, at a facilit y selected by  
the sponsor.  The duration allows the sponsor to respond to future regulatory  requests related to 
the IPs.  Any samples remaining af ter 15 y ears will  be destroy ed.
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule o f 
Activities (Section 2), where l ocal regulat ions allo w.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
LY3074828 and to investigate genetic variants thought to play  a rol e in autoimmune and 
inflammatory  diseases.  Assessment of variable response may include evaluat ion of AEs or 
differences in efficacy.  
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by the inves tigative site personnel.  
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 44
LY3074828Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and/or IRB impose shorter time limit s, for the study  at a f acility 
selected by  Lilly or i ts desi gnee.  This retention period enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the development of LY3074828 or after LY3074828 is commercially available.  
Molecular t echno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate gene studi es.  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion. 
9.8. Biomarkers
This sect ion is not applicable for this study.
9.9. Health Economics
This sect ion is not applicable for this stu dy.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 45
LY307482810. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
A total o f approximately  72 subjects (approximately  36 subjects per study  Parts A and B) who 
fulfill the eligibilit y criteria will  be randomized to 1 of 2 dosing regimen arms wit hin their 
assigned study  part, wi th 18subjects randomized to each arm in orde r to ensure completion o f 
16subjects in each.  The estimated total variabilit y (coefficient of variat ion) in AUC from time 
zero to infinit y AUC(0-∞), AUC fro m time zero to time t, where t is the last sample with a 
measurable concentration ( AUC [0-tlast]), and maximum observed drug concentration (C max)was 
49%, 49%, and 23%, respectively, in Study  AMAA fo llowing a single SC dose of 120 mg 
LY3074828.  The coefficient of variation o f 49% was used for precision estimates and is 
assumed for all dosing regimen arms.  A sample size of 64 subjects will provide a precision, in 
log scale, of approximately 0.28 for the geom etric means rati o in AUC( 0-
∞), AUC(0- tlast), and 
Cmaxof 1-to 2-mLsolution formulation inject ion.  That i s, there is a 90% probabilit y that the
half-length of the 90% confidence interval ( CI)of the geom etric means rati o in l og scale is not 
larger than 0.28.  Subj ects who are randomized but not administered treatment, or subjects that 
are administered treatment but do not have PK and ADA samples collected up to and including 
Day 57, m ay be repl aced (maximum of 4 per arm per study  part) to ensure that approximately  
16subjects from each dosing regimen arm com plete the study .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed descript ion of subject disposit ion will be provided at the end of the study . 
10.2.2. Study Participant Characteristics
The subject’s age, sex, weight, BMI, height, race/subrace, and other demographic data will be 
summarized by  dosing regimen and overall.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee.
Pharmacokinet ic analyses will be conducted on the full analysis set.  This set includes all data 
from all randomized subjects receiving the dose of LY3074828 with evaluable PK data in Part A .  
Safety analyses will be conducted for all subjects receiving a dose of LY3074828, whether or not 
they com pleted all protocol requirements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the resul ts of other studies for populat ion PK analysis purposes to 
avoid issues with post -hoc analyses and inco mplete di sclosures of ana lyses.  
No adj ustments for multiple com parisons will be made.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 46
LY307482810.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IPand protocol  procedure AEs and PCs will be listed, and if the frequency  of events all ows, 
safet y data will be summarized using descriptive m ethodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with IPas perceived by the invest igator.  Symptoms reported to occur prior to study entry will be 
distinguished from those reported as new or increas ed in severit y during the study .  Each 
symptom  will be classified by  the m ost sui table term fro m the medical regulatory  dictionary.
The number of IP-and device -related SAEs and any  related PCs will be reported.
10.3.1.2. Statistical Evaluation of Safety
10.3.1.2.1. Injection- sitePain
For Part sA and B, the intensit y of pain at each injection site immediately (approximately wit hin 
5 minutes) following the start of the inject ion will be evaluated, as reported by  the subject and 
measured according to the 0 to 100 mm VAS that for ms part of the SF -MPQ.   Assessments will 
also be performed at 15, 30, 60, 120, and 240 minutes post inject ion;however, the primary 
endpo int will be the 0-hour assessment. 
Descript ive statistics will be used to summarize the intensit y and ty pe of pain at each time point
as captured by  the SF -MPQ.
In Part A, a linear fixed -effects model will be used to analyze the 0-hour (post -inject ion)pain 
VAS score and SF- MPQ total  score.  The m odel will include treatm ent (Reference or Test 1) as a 
fixed effect .  The least squares (LS) means and differences in LS means (between Test 1 and 
Reference) will be presented along with the corresponding 90% CI.   
The distribut ion of the data 
will be explored prior to analysis to determine whether data transformation is required .  It i s 
possible that the pain scores will be 0 so if the distribut ion of the data implies that a 
log-transform ation is required then the score may be updated to log(VAS+1) to allow for the 
inclusio n of the 0 values in the analysis.
A similar model will b e used to analyze the 0-hour (post -inject ion)pain VAS score and SF -MPQ 
total score in Part B.  
The fo llowing com parisons will be performed in Part B:
Test 2 versus Test 3 (slow versus fast inject ion for 2-mL AI)
Test 4 versus Test 5 (slow versus fast inj ection for 1-mL AI) 
10.3.1.2.2. Duration of Injection
The durati on of  the inject ion (measured in seconds) will be summarized for each drug delivery  
device for each dosing regimen .
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 47
LY307482810.3.1.2.3. Injection- siteAssessments
Incidence of ery thema, induration, categorical pain, pruritus, edema, and bleeding will be listed 
and summarized by dosing regimen .  
10.3.1.2.4. Statistical Evaluation of Other Safety Parameters
Other s afety param eters that will be assessed include clinical laborator y param eters, vi tal signs, 
and ECG parameters.  The parameters, and changes from baseline (predose) where appropriate, 
will be listed and summarized using standard descript ive statist ics.  Addi tional analyses will be 
perform ed if warranted upon review of t he data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
For Part A, PK parameter estimates for LY3074828 will be calculated by standard 
nonco mpart mental methods of analysis.
The primary  parameters for analysis will be AUC( 0-∞), AUC(0 -tlast) ,and C maxfor LY3074828.  
The secondary  param eter for analysis will be the time to m aximum  observed drug concentration
(tmax) of LY3074828.  Other noncompart mental param eters, such as t 1/2, apparent total body  
clearance of drug cal culated after extra -vascular administration (CL/F), and apparent volume of 
distribut ion during the terminal phase after extra -vascular administration (V z/F),may be 
reported.
For Part B, no PK parameters will be evaluated.  Pharmacokinet ic samples are collected only in 
conjunction with immunogenici ty samples to provide serum concentrati ons of LY3074828 to aid 
in the interpretation of ADA data if needed .  Samples will be stored and will only be sent for 
bioanalysis at a later date based on immunogenicit y or saf ety resul tsfrom Part B of the study .
10.3.2.2. Pharmacokinetic Statistical Inference
For Part A, t he AUC( 0-∞), AUC(0- tlast), and C maxwill be log- transformed and analyzed using 
linear fixed- effects model.  The m odel will include dosing regimen arm as a fixed effect.  The 
dosing regimen differences between the Test 1 arm and the Reference arm  will be 
back-transformed to present the ratios of geometric LSmeans and the corresponding 90% CI.
The t maxof LY3074828 between the 2 x 1- mL PFS ( Reference) and the 1 x 2-mL PFS (Test1) 
will be analyzed using a Wilcoxon rank sum test for Part A.  Estimates of the median difference, 
90% CIs, and p
-values from the Wilco xon rank sum test will be calculated.
Addit ional PK analyses may be conducted for Part A if deemed appropriate.
10.3.3. Pharmac odynamic Analyses
This sect ion is not applicable for this study.
10.3.4. Pharmacokinetic/Pharmacodynamic Analyses
This sect ion is not applicable for this study.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 48
LY307482810.3.5. Evaluation of Immunogenicity
The frequency of format ion of antibodies to LY3074828 will be determined. 
Treatment -emergent ADAs are those that are induced or boosted by exposure to study drug, with 
a 4-fold or greater increase in t iter com pared to baseline if ADAs were detected at baseline, or a 
titer 2-fold greater than the minimum required dilution (1:10) if no ADAs were detected at 
baseline.
If a neutralization assay is performed, the frequency o f neutralizing ant ibodies will be 
determined.  The relat ionship between the presence (or absence) of ant ibodies and clinical 
param eters (AEs) will be assessed.  L ikewise, the relat ionship between the presence of 
antibodies and the PK parameters orconcentrations of LY3074828 may be assessed if deemed 
appropriate .  
10.3.6. Data Review During the Study
Data m ay be accessed and analyzed while the trial is ongoing, but no changes to the study design 
are planned.  An assessment committee will not be formed.
For Part sA and B of the study , available safet y data will be reviewed at approximately Day 30 in 
order to review emerging safet y and tol erabilit y data.
For Part A of th e study , data review is scheduled to occur when safet y and PK data through 
approximately  Day  57 (8 weeks postdose) become available for at least 12 subj ects f rom each 
dosing regimen arm .  The purpose of the data review is to trigger Chemistry , 
Manufacturing, and 
Control  processes with respect to LY3074828 formulat ion, and to inform dose select ion for 
Phase 3 first registration.
10.3.7. Interim Analyses
An exploratory  interim analysis is planned for this study . This will be for internal purposes only .  
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 49
LY307482811. References
Cornelissen F, Asmawidjaja PS, Mus AM, Corneth O, Kikly K, Lubberts E. IL -23 dependent and 
independent stages of experimental arthrit is: no clinical effect of therapeutic IL -23p19 
inhibit ion in co llagen -induced arthrit is. PLoS One . 2013;8(2):e57553.
Melzack R. The short -form McGill  Pain Questionnaire. Pain . 1987;30(2):191 -197.
Ruutu M, Thomas G, Steck R, Degli- Espost i MA, Zinkernagel MS, Alexander K, Velasco J, 
Strutton G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly K, Davies J, Pe ttit AR, Brown 
MA, McGuckin MA, Tho mas R. β -glucan tri ggers spondylarthrit is and Crohn's disease -like 
ileitis in SKG mice. Arthritis Rheum . 2012;64(7):2211 -2222.
Sampson HA, Muñoz -Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown 
SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, 
Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, 
Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the 
definit ion and manage ment of anaphylaxis: summary  report -Second National Institute of 
Allergy  and Infecti ous Disease/Food Allergy  and Anaphylaxis Network symposium. J Allergy 
Clin Immunol . 2006;117(2):391 -397.
Williamson A, Hoggart B. Pain: a review o f three commo nly used pa in rat ing scales. J Clin 
Nurs . 2005;14(7):798 -804.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 50
LY3074828Appendix 1. Abbreviations and Definitions
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 51
LY3074828Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
AI autoinjector
ALP alkaline phosphatase
ALT alanine aminotransferase
AUC area under the concentration versus time curve
AUC( 0-∞) area under the concentration versus time curve from time zero to infinity
AUC(0 -tlast) area under the concentration versus time curve from time zero to time t, where t is the last 
sample with a measurable concentration
BMI body mass index
CD Crohn’s disease
CI confidence interval
CL/F apparent total body clearance of drug calculated after extra -vascular administration
Cmax maximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the trial -related requirements, good clinical practice requirements, and the 
applicab le regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP clinical pharmacologis t
CPK creatine phosphokinase
CRP clinical resea rch phy sician
CRU clinical research unit
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 52
LY3074828ECG electrocardiogram
eCRF electronic case report form
ED early  discontinuation
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the trial are those 
who have been assigned to a treatment.
enter Subjects entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
GCP good clinical practice
GMP good manufacturing practice
GPS Global Patient Safety
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IFU Instructio ns for Use
IL-23 interleukin -23
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
subject’s decision to participate.  Informed consent is documented by means of a written, 
signed, and dated informed consent f orm.  
interim analysis An interim analysis is an analysis of clinical trial data, separated into treatment groups, that 
is conducted before the final reporting database is created/locked.
investigator A person responsible for the conduct of the clinical trial at a trial site.  If a trial is conducted 
by a team of individuals at a trial site, the investigator is the responsible leader of the team 
and may be called the principal investigator.
IP investigational product
IRB institutional review board
IV intravenous(ly)
LS least squares
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 53
LY3074828PC product quality complaint
PFS pre-filled syringe
PK pharmacokinetic(s)
Q4W every 4 weeks
Q8W every 8 weeks
SAE serious adverse event
SC subcutaneous (ly)
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial.   
SF-MPQ Short Form McGill Pain Questionnaire
SFS semi -
finished syringe
SUSAR suspected unexpected serious adverse reaction 
t1/2 half-life associated with the terminal rate constant
TB tuberculosis
TBL total bilirubin
TE-ADA treatment -emergent anti -drug antibody
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state , and does not necessarily have to have a causal relationship with this 
treatment. 
tmax time to maximum observed drug concentration
ULN upper limit of normal
VAS visual anal og scale
Vz/F apparent volume of distribution during the terminal phase after extra -vascular 
administration
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 54
LY3074828Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology a Clinical Chemistry a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Calcium
Mean cell volume Phospho rus
Mean cell hemoglobin Glucose (random)
Mean cell hemoglobin concentration Blood urea nitrogen (BUN)
Leukocytes (WBC) Uric acid
Cell m orphology Total cholesterol
Absolute counts of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin c
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Platelets Creatinine
Creatine phosphokinase (CPK)
Urinalysis a Ethanol testing d
Specific gravity Urine drug screen d
pH QuantiFERON -TB Gold test a,e
Protein
Glucose Serology e
Ketones Hepatitis B surface antigen
Bilirubin Hepatitis B core antibody
Urobilinogen Hepatitis C antibody
Blood HIV antibodies
Nitrite
Microscopic examination of sediment b Serum Pregnancy test f,g
Hormone Panel
Follicle -stimulating hormone e,h
Abbreviations:  HIV = human immunodeficiency virus; RBC = red blood cells; TB = tuberculosis; WBC = white 
blood cells.
aResults will be validated by the local laboratory at the time of initial testing.
bIf clinically indicated, per investigator’s discretion.
cIf total bilirubin is elevated, direct bilirubin and indirect bilirubin may be measured.
dUrine drug screen and ethanol level (determined via breath or urine testing) will be performed locally at 
screening and on Day -1 during admission to the clinical research unit.  May be repeated at the discretion of the 
investigator . 
ePerformed at screening only.
fFor all females at scree ning and onDay -1,and only  for w omen of childbearing potential at sampling time points 
thereafter .
gRefer to Section 2for specific sampling timing.
hTo be done for women to confirm postmenopausal status.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 55
LY3074828Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential ris ks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the informed consent form 
(ICF) prior to the performance of any  protocol  procedures and prior to the administration 
of investigational product.
answering any quest ions the subject may have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be rel evant to the subject ’swillingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Recruitment
Lilly ,or its designee ,isresponsible for the central recruitment strategy  for subject s.  Individual 
investigators may have addit ional local requirements or processes.   Study -specific recruit ment 
materi al should be approved by Lilly .
Ethical Review
The invest igator must give assurance that the institutional review board ( IRB) was properly 
constituted and convened as required by Internat ional Council for Harmonisation ( ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  IRB app roval  of the protocol  and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on good clinical practice ( GCP )
.
The study  site’s IRB(s) shoul d be provided wi th the f ollowing:
the current Invest igator’s Brochu reand updates during the course of the study
ICF
relevant curri cula vi tae
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 56
LY3074828Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences Internat ional Ethical Gu idelines 
2)applicable ICH GCP Guidelines 
3)applicable laws and regulations
Some of the obligat ions of the spons or will be assigned to a thirdparty  organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirm ing that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
The final report coordinat ing invest igator or designee will sign the clinical study report for this 
study , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the condu ct and resul ts of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate.
provi de training to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the electronic case report forms 
(eCRFs ), and study  procedures.
make periodic visit s to the study  site.
be availa ble for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collect ion.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 57
LY3074828conduct a qualit y review of the database .
In addit ion, Lilly or i ts representatives will periodically check a sample of the subject data
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and appli cable IRBs wi th direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The si te must define and retain all 
source records and must maintain a record of any  data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of subject personal information collected will be provided in a written 
docum ent to the subject by  the sponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly or its designee, the invest igator, or the IRB 
of the study  site judges i t necessary for m edical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee jud ges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 58
LY3074828Appendix 4. Hepatic Monitoring Tests for 
Treatment -emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subjec ts in consultation with Lilly or its designee clinical research 
physician/scient ist.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST Alkaline phosphatase isoenzymes a
GGT
CPK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 59
LY3074828Appendix 5. Blood Sampling Summary
The following tablessummarize the approximate number of venipunctures and blood volumes 
forall blood sam pling (screening, safet y laboratories, a nd bioanalyt ical assays) during the study .  
Fewer venipunctures and blood draws may actually occur, but this will not require a protocol 
amendment.
Proto col I6T-MC -AMAQ Sampli ng Summary –Part A
PurposeMaximum Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 5 62.5
Pharmacokinetics b 2 17 34
Immunogenicity a 10 5 50
Pregnancy tests 3.5 4 14
Pharmacogenetics 10 1 10
Total 190
Total for clinical purposes [rounded up to nearest 10 mL] 190
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples to be matched to additional immunogenicity samples (see 
Section 9.6.1) .
Proto col I6T -MC -
AMAQ Sampli ng Summary –Part B
PurposeMaximum Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 4 50
Pharmacokinetics b 2 7 14
Immunogenicity a 10 4 40
Pregnancy tests 3.5 4 14
Pharmacogenetics 10 1 10
Total 147.5
Total for clinical purposes [rounded up to nearest 10 mL] 150
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 60
LY3074828Appendix 6. Protocol A mendment I6T-MC-AMAQ(b)
Summary :A Safety , Tolerability , and Pharmacokinetic 
Study  of 1-and 2 -mL Injections of LY3074828 Solution 
Using Investigational Pre -filled Syringes and 
Investigational Autoinjectors in Healthy  Subjects
Overview
Protocol I6T-MC-AMAQ ,A Safety, Tolerability, and Pharmacokinetic Study of 1 -and 2 -mL Injections 
of LY3074828 Solution Using Investigational Pre -filled Syringes and Investigational Autoinjectors in 
Healthy Subjects ,has been amended.  The new protocol is indicated by Amendment (b)and will be used 
to conduct the study in place of any preceding version of the protocol.
The overall changes and rationale for the changes made to this pro tocol are described in the following 
table:
Table AMAQ. 4. Amendment Summary for Protocol I6T -MC-AMAQ Amendment (b)
Section # and Name Descriptio n of Change Brief Rationale
Section 10.3.7. Interim Analysis An update has been made to 
introduce an exploratory interim 
analy sis to this study .An exploratory interim analysis is 
planned for this study.
I6T-MC-AMAQ (b)Clinical Pharmacology Protocol Page 61
LY3074828Revised Protocol Sections
Note: All deletions have been identified by strikethroughs .
All additions have been identified by the use of underscore .
10.3.7. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the Lilly CP, CRP/investigator, or designee will consult with the appropriate medical 
director or desi gnee to determine if it is necessary  to am end the protocol .An exploratory interim 
analysis is planned for this study . This will be for internal purposes only. 
PPDLeo Document ID = 80a780ee-b11a-4f91-bf13-92570501d634
Approver: 
Approval Date & Time: 26-Jul-2018 19:03:41 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 26-Jul-2018 19:03:41 GMT
Signature meaning: ApprovedPPD